ANNUAL REPORT
2024-25



Al-Madina Pharmaceuticals Ltd.

Core Value


UNITY
RESPONSIBILITY
IDEAS
HONESTY
SHARING
Sustainability

Listing Photo Gallery











Al- Madina Pharmaceuticals limited is a famil- iar pharmaceuticals company in this sector. Al -Madina Pharmaceuticals limited started its journey for veterinary drugs in 2007 and human pharma in 2019. We are producing quality products, ensuring good services, main- taining sophisticated LAB and technology to grow up our business.

Al-Madina Pharmaceuticals limited ensures all complain for operation of factory and develop- ment of its products for increasing market share of the local pharma market significantly .

Al-Madina Pharmaceuticals limited has been designed to save the risk, maintain loss, accountability and record transaction properly. The company is maintaining a high standard of pollution free environment as per GMP regulation/WHO/government Laws.

Al-MadinaPharmaceuticals limited incorporated as a private Limited Company on July 27,2006 then converted to a public limited company on November 30, 2021. Furthermore, the company has listed with Dhaka Stock Exchange (DSE) and Chittagong Stock Exchange (CSE) on may 29, 2023.

At present the company existing resources and credit arrangement are deemed satisfactory to fulfill the immediate needs on its ongoing business activities.



TABLE OF CONTENTS


1. Corporate Overview 05
2. Our Vision and Mission 06
3. Letter of Transmittal 07
4. Notice of Annual General Meeting 08
5. Corporate Directory 10
6. Biography of Board of Directors, CFO and Company Secretary 11
7. Chairman Statement 14
8. Financial Highlights 15
9. Statement of Managing Director 16
10. Directors Report 18
11. Auditor's Report 48
12. Proxy Form 76

Corporate Overview:



Sl No	Particulars	Status
1.	Managing Director	Md. Zakir Hossain Patwary
2.	Board of Director	Md. Zakir Hossain Patwary Md. Billal Hossain Md. Kamrul Alam
3.	Enlisted	Dhaka Stock Exchange PLC Chittagong Stock Exchange PLC
4	Legal	RJSC
5	Type	Public Ltd Company
6	Authorized Capital	30,00,00,0000
7	Paid Up Capital	20,40,00,000
8	Number of Share	2,04,00,000
9	Major Products	Zolat Capsule, Thoraz 500 tablet, Raceper 20 Capsule, Claviator CV 250 Tablet, Anaprox Tablet, B3 Tablet, NS-Vet Powder, Tilvet Liquid, Set-3 Powder, Alcipro-vet Solution, Anticocci -K Powder.
10	Business Type	Manufacturing and Marketing
11	Major Sister Concerns	Smart Shoes Ltd. Royal Footwear Ltd. Royal Toiletries Ltd.
12	Debut Trading Date	29 .May 2023
13	Incorporation	Incorporated as a private limited company on July 27, 2006 then converted to public limited company on November 30, 2021

OUR VISION & MISSION



VISSION

Our endeavor is to serve the society in improving quality of life by delivering state of the art products and services through maintenance of high standards of ethics creating accelerated opportunities for the employees with innovative ideas



MISSION

To establish an environment around the pharmaceuticals field through the highest level of innovative and technical support which will add value to our society and act as a driven force of our humanity.

AL-MADINA

Letter of Transmittal

Date: 10. 12. 2025
All the Shareholders
Bangladesh Securities and Exchange Commission
Registrar of Joint Stock Companies & Firms
Dhaka Stock Exchange PLC.
Chittagong Stock Exchange PLC.


Subject: Annual Report for the year ended 30 June 2025

Dear Sir(s),
We are pleased to enclose a copy of the Annual Report containing Directors' Report, Auditors' Report along with Audited Financial Statements including statement of financial position as at 30 June 2025, Statement of profit or loss and Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2025.

The Proxy Form with Attendance Slip is attached at the end of the Annual Report for your use. In case of appointing a proxy, please complete the Proxy Form and submit it to our corporate office at least 48 hours before the scheduled meeting time. This will be our utmost pleasure to welcome you to the AGM of the Company.

Yours Truly

Md. Anwar Hossain
Company Secretary



Notice of Annual General Meeting

Notice is hereby given that the 19th Annual General Meeting of the Shareholders of Al-Madina Pharmaceuticals Ltd will be held on virtual media Link: https://almadinapharma.bdvirtualagm.com on December 30, 2025 at 11.30 a. m to transact the following business:

Ordinary Agenda:

1. To receive, consider and adopt the Directors' Auditors' Report and Audited Financial Statements for the year ended 30th June 2025.
2. To Approve Dividend for the year ended 30th June 2025 as recommended by the Board of Directors of the Company.
3. To Appoint Auditor of the Company and fixation of their remuneration for the year 2025-2026 as per ICAB Guideline.
4. To Retire/elect/re-elect the Directors of the Company.
5. To transact any other business with the permission of the chair

Special Agenda:

6. To Change the registered name of the company to "Al-Madina Pharmaceuticals PLC" from Al-Madina Pharmaceuticals Ltd.

By order of Board of Directors

Dated: Dhaka
December 02, 2025

Md. Anwar Hossain
Company Secretary

Notes:

1. The record date for this AGM was 4th November 2025. The shareholders whose name will appear in the Depository/Share Register on the record date will be entitled to the dividend.
2. A member eligible to attend the Annual General Meeting is entitled to appoint a proxy to attend on his/her behalf.
3. Form or Proxy, duly completed and stamped, must be deposited at company's share Department at least 48 hours before the time appointed for the meeting and in default it will not be trusted as valid.
4. Members are requested to notify change of address, if any, to the company.
5. 19th AGM of the Company shall be conducted through virtual media link: https://almadinapharma.bd virtualagm.com.
6. The Company will send the link of the online live portal to attend the AGM to the shareholders in due course.
7. Soft Copy of the Annual Reports of the Company will be sent to the shareholder's respective e-mail addresses if any shareholder wants to see it.
8. Annual Reports will be available on the Company website: https://almadinapharma.com
9. The members are able to submit their question(s) and vote electronically 48 hours before commencement of the AGM and during the AGM.
10. Depository Participants (DPs)/Stock Brokers are requested to provide us with a list with particulars of margin loan accounts holding Al-MADINA PHARMACEUTICALS LTD. shares as on the record date along with the particulars of Bank A/C of the DP/Stock Brokers and soft copy of the same at anwar.cs.ampl @gmail.com within 13 December 2025 for receiving the dividends of the margin loan holders.

11. In compliance with the Bangladesh Securities and Exchange Commission's Circular No. SEC/ CMRRCD/ 2009-193/154 dated October 24, 2013; No benefit in cash or kind, other than in the form of cash dividend or stock dividend shall be paid to the holders of the equity securities at the 19th AGM of the Company.

12. Retirement/election/re-election of Directors of the Company will be conducted in compliance with the Companies Act, 1994, the Articles of Association of the Company and other prevailing relevant rules & regula- tions of the country.

Corporate Directory:
Board of Directors:

Chairman:
Md. Billal Hossain

Managing Director:
Md. Zakir Hossain Patwary

Director:
Md Kamrul Alam

Chief Financial Officer (CFO):
Mohammad Anichur Rahman

Company Secretary:
Mohammad Anwar Hossain

Head of Internal Audit:
Mr. Nazrul Islam

Executive Management Committee:
Md.Zakir Hossain Patwary, Managing Director
Md. Billal Hossain, Chairman
Md. Kamrul Alam, Director
Mohammad Anichur Rahman, CFO
Mohammad Anwar Hossain, Company Secretary
Md. Mostafa Kamal, AGM,Sales
Md. Shah Alam, Manager, National Sales
Md.Rafiqul Islam, G.M (Plant Operation)
Md.Shamim Howlader, Manager (HR and Adminstration)

Statutory Auditor:
Md Anwar Hossain, FCA Partner
Anil Salam Idris & Co Chartered Accountants
House#1/B (3rd Floor),Road #08 Block 1, Banani,
Dhaka-1213 Bangladesh

Listing:
1. Dhaka Stock Exchange PLC.
2. Chittagong Stock exchange PLC

Registered Office:
1/1, Tilargati, Kakil, Tongi-1711, Gazipur.

Corporate Office:
178-179, Tejturi Bazar Road, Farmgate, Dhaka.

Factory:
1/1,Tilargati,Kakil, Tongi-1711,Gazipur.

Main Bankers:
Islami Bank Ltd.
Shahjalal Islami Bank Ltd.
Pubali Bank ltd.
IFIC Bank Ltd.
Al-Arafah Bank Ltd.
Dutch Bangla Bank Ltd.

Biography of Board of Directors, CFO and Company Secretary:



Md Billal Hossain
Chairman

Mr. Billal Hossain was born in a prominent Muslim family living in Laximpur. He has completed his graduation in BSc. He has over 21 years experienced in Pharmaceuticals, Footwear, Toiletries, Agro, Construction and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, designing, indicating and implementing in financing, investing and operating successfully. He is well organizer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. Also, has interest in number of Companies (AL- Madina Pharma- ceuticals Ltd (Animal and Human Division), Royal Footwear Ltd (footwear), Smart shoes Ltd (Footwear), Royal Toiletries Ltd (Diaper and Toiletries), Marigold Real Estate Ltd (Construction and Development), Marigold Associate Ltd (Construction and Development), Tulip Super agro Industries Ltd. and proprietor of 02 No. of units M/S Belal and Brother and M/S Sciencet- ech Corporation.

Md Zakir Hossain Patowary
Managing Director



Md Zakir Hossain Patowary was born in a prominent Muslim family living in Laximpur. He has completed his Post graduation in M.Sc. He has over 21 years experienced in Pharmaceuticals, Footwear, Toilet- ries, Agro, Construc- tion and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, and designing, indicating and imple- menting in financing, investing and operating successfully. He is well organ- izer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. He also has interest in number of Limited Companies (AL - Madina Pharma- ceuticals Ltd (Animal and Human Division),Royal Footwear Ltd (footwear), Smart shoes Ltd(Footwear), Royal Toiletries Ltd(Diaper and Toiletries), Marigold Real Estate Ltd (Construction and Development),Marigold Associate Ltd (Construction and Development),Tulip Super agro Industries Ltd. and proprietor of 06 No. of units Al Madina pharmaceuticals, Al Madina Traders,Al Madina Printing Press, Tech Squard, Royal Shoes and Royal Motors.



Md Kamrul Alam
Director

Md Kamrul Alam was born in a prominent Muslim family living in Laximpur. He has completed his graduation in B.A. He has over 21 years experienced in Pharmaceuticals, Footwear, and Construction and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, designing, indicating and implementing in financing, investing and operating successfully. He is well organizer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. He was Director of 04 No. of Limited Company (AL -Madina Phar- maceuticals Ltd (Animal and Human Division), Royal Footwear Ltd (footwear), Smart shoes Ltd (Footwear), Marigold Real Estate Ltd (Construction and Development) and proprietor of M/S Care International.

Mohammad Anichur Rahman
Chief Financial Officer



Mohammad Anichur Rahman has completed Master of Business Adminis- tration, Major in Accounting from Islami University, Kushtia in 2000. He has a lot of Experience on Accounting, Finance Audit, Tax, Vat, Costing and Operations in the company. He has good knowledge on IFRS, IAS, Tax, Vat, and Company Operation. He is playing the significant role for developing of the Company. He is also serving as a Chief Operating Officer of the Company. He has more than 24 year's professional experience in different area



Mohammad Anwar Hossain
Company Secretary

Md. Anwar Hossain has completed Master of Business Administration, Major in Accounting from Rajshahi University in 2004.Has has also passed income tax practitioner examination under National Board of Revenue. He has a lot of Experience on Accounting, Finance Audit, Tax, Vat and Costing in different organization. He has a profound and wide spread knowledge on IFRS, IAS, Tax, Vat, RJSC, BSEC Rules and different law, rules and regulation. He has value added role play for the company. He has more than 21 year's professional experience in different organization.

Human Resources





Chairman Statement:



Dear Shareholders Assalamu - Alaikum

I am very pleased to welcome all the shareholders in the 19th Annual General Meeting of Al-Madina Pharmaceuticals Limited. Before that you have received the Annual Report along with Directors Report and Audited Financial Statements for the year ended 30th June 2025.

As you know that now we are facing unfavorable global and local situation due to war and economic policy. At this situation every Company are facing unexpected business situation. Most of company of our country has no avail raw materials as per their production and sales demand. After all we are proceeding our business through our proper planning, skill employees and proper use of our resources. The dedication of our employees will help to create the brands of our products.

Finally, on behalf of the board, I would like to congratulate and warmly thanks to all of our employees for their achievement throughout 2025. As well as thanks to our all shareholders, customers, suppliers, bankers and other stakeholders for their continual support to develop our business. We hope and believe, we will able to overcome all challenges in upcoming year.

I wish for success of the company in future. Yours truly

Md. Billal Hossain
Chairman

Financial Highlights:
Financial Position at a Glance:

Particulars	30 June 2025	30 June 2024	30 June 2023	30 June 2022	30 June 2021
ASSETS					
Non-Current Assets	306,986,090	308,873,618	317,176,332	333,166,382	328,029,470
Current Assets	278,888,951	314,513,316	322,700,893	214,101,090	144,709,219
TOTAL ASSETS	585,875,041	623,386,934	639,877,225	547,267,472	472,738,689
EQUITY AND LIABILITIES					
Equity attributable to the owners of the company	420,442,619	415,946,893	404,268,996	333,400,775	287,662,235
Non-Current Liabilities	6,372,638	14,967,974	15,589,991	15,257,539	16,412,304
Current Liabilities & Provisions	159,059,784	192,472,068	220,018,240	198,609,159	168,664,150
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	585,875,041	623,386,934	639,877,225	547,267,472	472,738,689
Net Asset Value Per Share with Revaluation	20.61	20.39	19.82	21.65	22.47
Net Asset Value Per Share without Revaluation	13.80	13.58	13.00	12.63	11.62

Statement of cash flows at a glance:

Particulars	30 June 2025	30 June 2024	30 June 2023	30 June 2022	30 June 2021
A. Cash Flow from Operating Activities	19,204,398	51,039,132	(26,323,262)	(8,401,604)	44,973,738
B. Cash Flow from Investment Activities	(16,402,908)	(11,062,642)	(7,690,815)	(24,516,710)	(68,871,538)
C. Cash Flow from Financing Activities	(47,215,253)	(31,961,090)	59,608,466	37,541,951	22,464,836
D.Net cash flow for the year (A+B+C)	(44,413,763)	8,015,400	25,594,389	4,623,638	(1,432,964)
E. Opening Cash and Cash Equivalents	50,231,137	42,215,736	16,621,348	11,997,710	13,430,674
F. Closing Cash and Cash Equivalents	5,817,374	50,231,137	42,215,736	16,621,348	11,997,710

Revenue at a Glance:

Particulars	30 June 2025	30 June 2024	30 June 2023	30 June 2022	30 June 2021
Sales Revenue	481,684,250	644,127,729	685,624,856	668,965,108	556,164,433
Gross Profit	221,513,267	292,134,623	280,726,968	270,668,403	205,339,144
Operating Profit	35,834,670	44,740,406	48,272,126	46,201,758	43,581,370
Net Profit / (Loss) for the year Before WPPF	16,350,702	26,624,985	33,756,479	33,880,603	30,773,331
Net Profit / (Loss) before Tax	15,572,097	25,357,129	32,149,027	32,267,241	29,307,934
Net Profit / (Loss) after Income Tax	11,875,726	17,827,897	25,166,171	19,738,540	23,188,337
Other Comprehensive Income:		-	-	-	138,967,050
Revaluation Reserve		-	-	-	143,265,000
Total Comprehensive Income	11,875,726	-	25,166,171	19,738,540	162,155,387
Earnings Per Share Basic	0.58	0.87	1.57	1.30	33.99

Statement of Managing Director:



Dear Shareholders
Assalamu -Alaikum.

With hope and gratification, I cordially welcome the shareholders in the 19th Annual General Meeting of AL-Madina Pharmaceuticals Ltd. We are going to arrange 19th Annual General Meeting through online platform. It is our pleasure to present you in this Annual General Meeting.

We have been operating our business from long time with goodwill. We have started our business with Agrovet division. After that we have added Pharma division. We have developed our business through our commitment. Now, we are facing so many challenges to operate our business. At this moment, we are facing so many difficulties to arrange raw materials as per our demand due to start the war and unfavorable global business policy. We hope we will be able to overcome this limitation through our proper plan and skill very soon. After all, by the grace of Almighty Allah, we are pleased for report of successful year 2025.The Company is stated the financial position (summery) for the year ended June 30, 2025 in following way.

Particulars	**Amount BDT**
Sales Turnover	48,16,84,250
Gross profit	22,15,13,267
Operating Profit	3,58,34,670
Net Profit after Tax	1,18,75,726
Net Asset value per share with revaluation	20.61
Earnings Per share	0.58

We will able to add the new product based on market demand which will be significantly increasing our market share in upcoming years.

We are committed to maintain our product quality and given the patients smile on the face. We are constantly putting our effort to increase our market share and introduce the new products. At this moment, I remember my speech of last year AGM -2024 that We committed the declaration of best dividend to our stakeholder in AGM-2025. We have to able the fulfil of our commitment through declaration of good dividend. I hope it will be continuous in upcoming year.

Finally, I encourage to all of our shareholders, bankers, customers, suppliers, our employees for their support to develop our business. I am waiting for upcoming development of the company.

Yours sincerely

Md. Zakir Hossain Patwary
Managing Director



Al- Madina Pharmaceuticals Ltd













Directors Report:

Dear Shareholders

Assalam-Alaikum

The Directors are delighted to present the annual report together with the audited financial statements of the company for the year ended 30 June 2025.

This report has been prepared according to section 184 of the companies' act 1994 and Bangladesh Securities and Exchange Commission Notification No BSEC /CMRRCD/2006-158/207/admin/80 dated 3 June 2018. The directors have presented their report on certain issues which deemed relevant and significance to ensure the compliance.

Background of the company:

Al-Madina Pharmaceuticals Limited is a private limited company duly incorporated in Bangladesh on 27 July, 2006 under Companies Act 1994, vide Certificate of Incorporation No. C-62976(467)/06\, and its commercial operations commenced on 21 October, 2007.The Company Transitioned into a public Ltd Company on Nov 30,2021.Furthermore the company has listed with DSE and CSE on May 29,2023.

The address of the company are as follows:

Registered and Factory Office: 1/1, Tilargati, Kakil, Tongi-1711, Gazipur.
Corporate Head Office: 178-179, Farmgate, Tejturi Bazar Road, Road-23, Ward-39, Tejgaon, Dhaka.

Principal Activities:

The Company is engaged in the manufacturing, buying, selling, import, export or otherwise of phar- maceuticals and medicinal products, and preparations, patent drugs and proprietary articles of all kinds, whether basic or derived and in all forms. Al-Madina Pharmaceuticals Limited has started a journey for veterinary drugs in 2006 and human drugs in 2019. At present, it is manufacturing veterinary drugs such as antibacterial drugs, nutritional products, poultry vaccines, aqua products, daily injectable products etc. and human drugs such as antibacterial drugs, anti-fungal drugs, gastro-intestinal drugs, analgesic & anti-inflammatory drugs, vitamins-minerals or supplements, drugs acting on urogenital system and drugs acting on respiratory system etc.

Business Risk:

Adhering to IFRS 7: Financial Instruments, the financial statement has been formulated with consideration of credit risk, liquidity risk, and market risk.

Credit Risk: The Company operates under a credit policy that guides credit issuance. Security measures, such as obtaining blank cheques from customers and counterparties, are implemented during credit sales, minimizing credit risk exposure..

Liquidity Risk: Liquidity risk arises from financial obligations. The Company's sales team is dedicated to adhere a systematic collection plan for sales proceeds. As a result, the Company's liquidity risk is kept at a minimum.

Property, Plant and Equipment:

The Company has invested total sum of tk 44.93 Core in Property, Plant and Equipment. Movement in Property, Plant and Equipment during the year in disclosed under note 4 of the Financial Statements.

Our Strenght:











Performance of the Company:

The revenue of Al-Madina Pharmaceuticals Ltd has been tk 48.17 Core during the year . Gross Profit has been tk 22.15 Core.Operating Profit has been tk 3.58 core.Net profit after tax has been tk 1.19 core

Existing Product List :

Agro vet Division:

DGDA Registered Products

Sl.	DAR No	Name of Product	Generic Name & Strength	Pack Size
1	294 -04(V)-77	Tylotrate20 Powder	Each 100 gm contains Tylosin Tartrate BP 22.50 gm (Eqv. to 20.00 gm of Tylosin BP)	100gm Sachet 500gm Container 1 kg Container
2	294 -06(V)-77	Almolin -Vet Powder (Vet)	Each 100 gram contains Amoxicillin Trihydrate BP 34.50gm (Eqv.to 30.00gm of Amoxicillin BP)	100gm Sachet 500gm Container 1 kg Container
3	294 -07(V)-77	Alcipro Solution (Vet)	CEach 100 ml contains Ciprofloxacin HCL USP 11.644 (Eqv. to 10.00 gm of Ciprofloxacin USP)	100ml Bottle 500ml Bottle 1 Ltr Bottle
4	294 -09(V)-77	Altetra Bolus (Vet)	Each Bolus Contains Oxytetracycline HCL BP 540.00 mg (Eqv.to 500 gm of Oxytetracycline BP)	4 X 5' Bolus
5	294 -10(V)-77	Altetra Powder (Vet)	Each 100 gm powder contains Oxytetracycline HCL BP 21.60 gm	100gm Sachet 500gm Container 1 kg Container (Eqv.to20.00 gm of Oxytetracycline BP)

6	294 -13(V)-77	Cocsomix plus powder	Each 100 gm powder contains Sulfacholoropyridazine USP 10.000 mg + Trimethoprim BP 2.000gm	100gm Sachet 20 gm Sachet 500gm Container 1 kg Container
7	294 -14(V)-77	Wormfree Bolus(Vet)	Each Bolus Contains Albendazole USP 600.00 mg	4 X 5' Bolus
8	294 -15(V)-77	Al-Sulpha Bolus (Vet)	Each Bolus Contains Sulfadiazine BP 1.666 mg + Sulfadimidine BP 1.666 mg + Sulfapyridine BP 1.666 mg	4 X 5' Bolus
9	294 -16(V)-77	Hemorex Bolus (Vet)	Each Bolus Contains Cobalt Sulphate BP 50.000 mg + Ferrous Sulphate BP 100.000 mg + Thiamine Mononitrate USP 25.000 mg + Vitamin 10B12 USP 20.000 mg + Choline Bitartrate BP 9.100 mg	4 X 15' Bolus
10	294 -17(V)-77	Helmacid – Vet Poowder	Each 100 gm powder contains Piperazine Citrate BP 100.000gm (Eqv.to36.000 gm of Piperazine BP)	500gm Container 100gm Sachet 20 gm Sachet
11	294 -18(V)-77	Alenro-Vet Solution	Each 100 ml solution contains Enrofloxacin INN 10.00 gm	100ml Bottle, 500 ml, 1 ltr
12	294 -19(V)-77	Alcocci Powder (Vet)	Each 100 gm powder contains Sulphaclozine Sodium Monohydrate INN 30.000 gm	500gm Container 100gm Sachet 20 gm Sachet
13	294 -20(V)-77	An-Worm Blous (Vet)	Each Bolus contains Triclabendazole INN 900.00 gm + Levamisole HCL BP 707.13 mg (Eqv.to 600 gm of Levamisole BP)	4 X 5' Bolus

14	294 -21(V)-77	Almolin Vet Bolus	Each Bolus Contains Amoxicillin Trihydrate BP 575.00 mg (Eqv.to 500 mg of Amoxicillin BP)	2 X 10' Bolus
15	294 -23(V)-77	Promethazine Bolus (Vet)	Each Bolus Contains Promethazine Hydrochloride BP 150.00 mg	10 X 4' Bolus
16	294 -24(V)-77	Ferum Bolus (Vet)	Each Bolus Contains Antimony Potassium Tartrate USP 2000.00 mg + Ferrous Sulphate USP 2000.00 mg	4 X 5' Bolus
17	294 -25(V)-77	Amovet Bolus (Vet)	Each Bolus Contains Metronidazole BP 2000.00 mg	4 X 5' Bolus
18	294 -27(V)-77	SET- 3 Powder (Vet)	Each 100 gm powder contains Erythromycin Thiocyanate INN 18.00 gm + Sulphadiazine BP 15.000 mg + Trimethoprim BP 3.000 gm	10gm, 20gm,100gm Sachet 500gm Container 1 kg Container
19	294 -29(V)-77	Each Bolus Contains Antifever Bolus (Vet)	Paracetamol BP 2000.00 mg	10 X 2' Bolus
20	294 -30(V)-77	Anticocci – K Powder	Each 100 gm powder contains Sulphadimmethoxine BP 2.00 gm + Sulphadimidine BP 20.00 gm + Diaverdine BP 3.00 gm + Niccotinamide BP 3.00gm +VitaminK3 USP 2.00 gm	100gm Sachet 500gm Container 10x10gm, 10x20gm

21	294 -31 (V)-77	Sulmidine Bolus (Vet)	Each Bolus contains Sulphadimidine BP 5000.00 mg	10 X 2' Bolus
22	294 -32 (V)-77	Germfree Liquid (Vet)	Each 100ml solution contains Povidone – Iodine USP 10.00 gm	1 Ltr Bottle 100ml Bottle
23	294 -33 (V)-77	Trimosul Suspension (Vet)	Each 100 ml solution contains Sulphadiazine Sodium BP 40.00 gm + Trimethoprim USP 8.00 gm	1 Ltr Bottle 100ml Bottle 500ml Bottle
24	294 -34 (V) -77	Alvasol Powder (Vet)	Each 100gm powder contains Levamisole HCI BP 35.36 gm (Eqv.to 30.00gm of Levamisole BP)	10 X 100gm
25	294 -35(V)-77	Alcipro Bolus (Vet)	Each Bolus contains Ciprofloxacin HCL USP 873.00 mg (Eqv. to 750 gm of Ciprofloxacin USP)	10 X 2' Bolus
26	294 -36 (V)-77	NS- Vet Powder	Each 100gm powder contains Neomycin Sulphate BP 50.00 gm	100gm Sachet 500gm Container 1 kg Container 20 gm Sachet
27	294 -38(V)-77	Altetra- Vet LA Injection	Each 10 ml contains Oxytetracycline Dihydrate (Sterile) BP 2.157 gm (Eqv.to 2gm Oxytetracycline)	10ml Amber Colored 50ml.Amber Colored
28	294 -39(V)-77	Algenta - Vet Injection	Each 10 ml contains Gentamycin Sulphate (Sterile) BP 1.70 gm (Eqv.to 1 gm of Gentamcin)	10ml Amber Colored glass 100ml Amber Colored glass Vial
29	294 -40 (V)-77	Nitroworm - Vet Injection	Each 10 ml contains Nitroxynil BP 3.4 gm	10ml Amber Color glass Vial 100ml Amber Color glass Vial
30	294 -41 (V)-77	Hyvit ADE- Vet Injection	Each 10 ml contains Vitamin A Palmitate BP 5,000,000 IU + Vitamin D3(Colecalciferol) BP 750,000 IU + Vitamin E Acetate BP 500 mg	10ml Amber Colored glass Vial 100ml Amber Colored glass Vial

31	294 -42 (V)-77	Albu - Vet Injection	Each 10 ml contains Buparvaquone BP 500 mg	10ml Amber Color glass Vial 50ml, Amber Color glass Vial
32	294 -43 (V)-77	Alhista Vet Injection	Each 10 ml contains Pheniramine meleate BP 227.5 mg	10ml Amber Colored glass Vial 100ml,Amber Colored glass Vial
33	294 -44 (V)-77	Calplus- Vet Injection	Each 10 ml contains Calcium Gluconate BP 2.08 gm + Magnesium Hydrophosphite BP 0.50 gm + Dextrose Monohydrate BP 2.00gm	100ml Amber Colored glass Vial
34	294 – 45 (V)-77	Fatisol – Vet Injection	Each 10 ml contains Butaphosphan INN 1.0 gm + Cyanocobalamin BP 500 mcg	10ml Amber Colored glass Vial 100ml Amber Colored glass Vial
35	294 – 046 (V)-077	Al-Doxil Powder (Vet)	Each 100 gm powder contains Doxycycline Hydrochloride BP 11.500 gm (Eqv. to 10.00 gm of Doxycycline)	100gm Sachet 500gm Container 1 kg Container 20 gm Sachet
36	294 -047(V)-077	Mexicam Bolus (Vet)	Each Bolus contains Meloxicam BP 100.00 mg	4 X 10’ Bolus
37	294 -048(V)-077	T-Zuril Vet Liquid	Each 100 ml contains Toltrazuril BP 2.50 gm	500ml Bottle 1 Ltr Bottle 100ml Bottle
38	294 -049(V)-077	Tilvet Liquid (Vet)	Each ml contains Tilmicosin phosphate USP 250.00 mg	500ml Bottle 100ml Bottle
39	294 -051(V)-077	Summer Cool Powder (Vet)	Each 100 gm powder contains Acetyl Salicylic Acid BP 6.70gm + Vitamin – C USP 20.0gm	100gm,500gm sachet ,1kg container

40	294 -68(V)-77	AL-CTC Vet Powder	Each 100 gm contains Chlortetracycline Hcl BP 20.0 gm	100gm sachet , 500gm, 1 kg Container
41	294 -69 (V)-77	LV-VET Powder	Each 100 gm contains Levofloxacin Hemihydrate USP 10.25gm (Eqv. To 10.0 gm Levofloxacin)	100gm sachet , 500gm, 1 kg Container
42	294 -70(V)-77	AMPO – VET Powder	Each 100 gm contains Amprolium Hydrochloride BP 20.0gm	100gm sachet , 500gm, 1 kg Container
43	294 -71(V)-77	ALCIPRO –VET Bolus	Each Bolus Contains Ciprofloxacin Hydrochloride USP 1164.00mg (Eqv. to 1000.00 mg of Ciprofloxacin USP)	(10 x 2'S) Bolus
44	294-99(V)-77	Tylva-Vet Powder	Each 100 gm contains- Tylvalosin Tartrate INN 71.5gm (Eqv. To 62.5gm of Tylvalosin)	100gm, 500gm, 1kg
45	294-109(V)-77	Altiguard- Vet Powder	Each 100gm contains- Tiamulin Hydrogen Fumerate Bp 45.00gm	100gm, 500gm, 1kg
46	294-110(V)-77	Amovet Powder	Each 100gm powder contains- Metronidazole BP 30.00	100gm, 500gm, 1kg
47	294-133(V)-77	Gout-Free Powder (Vet)	Each 100 gm contains-Allopurinol USP 5gm	10gm, 20gm, 100gm, 500gm, 1kg
48	294-134(V)-77	Nephro-Vet Powder	Each 100 gm powder contains- Methenamine BP 95gm, Vitamin B1 BP 0.8gm, Vitamin B2 BP 0.1gm, Vitamin K3 USP 0.2gm,	10gm, 20gm, 100gm, 500gm, 1kg

49	294-135(V)-77	IVMEC 1% Solution (Vet)	Each 100 ml liquid contains Ivermectin BP 1gm	15ml, 100ml, 500ml, 1000ml
50	294-136(V)-77	AL-TDOX PLUS Powder (Vet)	Each 100 gm powder contains- Bromhexine HCl BP 2gm, Doxycycline Hyclate BP 20gm, Tylosin Tartrate BP 10gm	10gm, 20gm, 100gm, 500gm, 1 kg
51	294-137 (V)-77	Algenta-Vet Oral Powder	Each 100 gm contains Gentamicin Sulphate BP 33.90gm (Equivalent to 20gm Gentamicin)	10gm, 20gm, 100gm, 500gm, 1 kg
52	294-138(V)-77	Alvasol Bolus (Vet)	Each Bolus contains Levamisole HCl BP 708 mg (Equivalent to 600mg Levamisole)	10x2 bolus, 10x4 bolus, 4x15 bolus
53	294-139 (V)-77	An-Worm DS Bolus (Vet)	Each Bolus Contains Triclabendazole BP 1800mg, Levamisole BP1414.39mg (Equivalent to 1200mg)	10x2 bolus, 10x4 bolus, 4x15 bolus
54	294-140 (V)-77	An-Worm MS Bolus (Vet)	Each Bolus Contains Triclabendazole BP 1200 mg, Levamisole BP 884 mg (Equivalent to 750 mg)	10x2 bolus, 10x4 bolus, 4x15 bolus
55	294-154 (V)-077	Antifever Powder (Vet)	Each 100 gm powder contains Paracetamol BP 50gm	10x10gm, 10x20gm, 10x100gm, Alu-Alu Sachetr, 500gm, 1kg container
56	294-155(V)-077	Altetra DS Bolus (Vet)	Each Bolus Contains- Oxytetracycline Hydrochloride BP 1079.28mg (Equivalent to Oxytetracycline 1000mg)	10x2, 5x4, 10x4, 15x4 Bolus

57	294-156 (V)-077	Al Zinc Vet Bolus	Each Bolus Contains Zinc Sulphate Monohydrate USP 549mg(Equivalent to Elemental Zinc 200mg)	10x2, 5x4, 10x4, 15x4 Bolus
58	294- 157(V)-077	Triclaben Bolus (Vet)	Each Bolus Contains Triclabendazole BP 900 mg	10x2, 5x4, 10x4, 15x4 Bolus
59	294- 158(V)-077	Hemorex DS Bolus (Vet)	Each Bolus Contains- Cobalt Sulphate BP- 100mg, Dried Ferrus Sulphate BP 200 mg, Thiamine Mononitrate USP 50 mg, Cyanocobalamin BP 401mcg, Choline Bitartrate USP 18.250 mg.	10x2, 5x4, 10x4, 15x4 Bolus
60	294- 163 (V)-077	FC-Vet Oral Solution	Each 100 ml Contains – Florfenicol INN 20 gm	100 ml, 500ml, 1 Liter
61	627-4896(V)-18	BRONCHIPHARM (Vet)	Avian Infectious Bronchitis Virus, Live, strain H 120 Eurpharm $10^{3.0}$ EID_{50}-$10^{4.5}$ EID_{50}	100,500,1000,5000 Doses
62	627-4897(V)-18	BURSIPHARM (Vet)	Infectious Bursal Disease Virus, Live (strain 2512) Eurpham min.$10^{3,0}$ $TCID_{50}$	100,500,1000,2000, 5000 Doses
63	627-4898(V)-18	PESTIPHARM B1 (Vet)	Newcastle Disease Virus, Live, Strain Hitchner B1 Eurpharm $10^{6.0}$ EID_{50}-$10^{7.0}$ EID_{50}	100,500,1000,2000, 5000 Doses
64	627-4924(V)-19	AVIPHARM ND	Newcastle disease virus, Live Strain Ph. Eur. Min $10^{6.0}$ EID_{50}-max $10^{7.0}$ EID_{50}	100,500,1000,2000, 5000 Doses

DLS Category Product List:

190-19-(16)-001	**Biovit -ES**	Each ml Contains: Vitamin E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg, Biotin BP 50µg	100ml, 500ml, 1L
190-19-(16)-002	**Zinc Liquid**	Each 100 ml Contains: Zinc Sulphate Monohydrate BP 2.00 gm	100ml, 500ml, 1L
190-19-(16)-003	**Glu-C Vet**	Each 100 gm Contains: Glucose BP 98 gm & Vitamin C BP 2 gm	100gm, 500gm, 1kg
190-19-(16)-004	**Hyvit-ES**	Each ml Contains: Vitamin-E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg	100ml, 500ml, 1L
190-19-(16)-005	**Thiarip**	Each Kg Contains: Thiamine Hydrochloride BP 60.00 gm, Riboflavin Sodium-5 Phosphate BP 11.00 gm, Pyridoxine Hydrochloride BP 6.10 gm	100gm, 500gm, 1kg
190-19-(16)-006	**Hyzinc+B**	Each ml Contains: Zinc Sulphate Monohydrate BP 20.0 mg, Thiamine HCl BP 5.0 mg, Riboflavin Sodium-5 Phosphate BP 1.50 mg, Pyridoxine HCl BP 8.00 mg, Nicotinamide BP 4.0 mg	100ml, 500ml, 1L
190-19-(16)-007	**AM Hepaton**	Each Ltr. Contains: Vitamin B1 200 mg, Vitamin B2-5-phosphate 200 mg, Vitamin B6 200 mg Vitamin B12 200 mg, Pantothenol 1100 mg, Niacin 6000 mg, Folic Acid 30 mg, Betaine 4000 mg, Choline Chloride 5000 mg, L-Glycine 5000 mg, Vitamin K 65 mg, Inositol 100 mg, L-Lysine HCl 8000 mg, DL-Methionine 5000 mg L-Threonine 1000 mg, L-Tryptophan 250 mg, Sodium Propionates, Potassium Sorbate	100ml, 500ml, 1L, 25L
190-19-(16)-008	**AM Aminosol**	Each 1000 ml Contains: Vitamin A 15000000 IU, Vitamin D/Vitamin D3 200000 IU, Vitamin E 8000 mg, (as all-rac-alpha-tocopheryl acetate) Vitamin B1/Thiamine Mononitrate 1800 mg, Vitamin B2/Riboflavin-5-Phosphate ester monosodium salt 1300 mg, Vitamin B6/Pyridoxine Hydrochloride (3a831) 800 mg, Vitamin B12/Cyanocobalamin 12 mg, Nicotinic acid/Nicotinic acid amide(Nicotinamide) 12500 mg, Vitamin C/L-Ascorbic acid 22000 mg, Vitamin K (as Menadione Sodium Bisulfite) 1000 mg, Pantothenic acid/D-Panthenol 5000 mg, Folic acid 250 mg, Glutamic acid 150000 mg, L-lysine 80000 mg, Alanin 43000 mg, Valin 30000 mg, Aspartic acid 17000 mg, L-tryptofane 12000 mg, DL-Methionine 12500 mg, Cysteine 9000 mg, Histidine 3000 mg, Serine 5000 mg, Isoleucine 5000 mg, L-Threonine 5000 mg, Glycine 5000 mg, Proline 4000 mg, Leucine 4000 mg, Arginine 4000 mg, Tyrosine 3000 mg	100ml, 500ml, 1L 25L
190-19-(16)-009	**AM Layer Premix**	Each 2.5 Kg Contains: Vitamin A 12,000,000 IU, Vitamin D3 2,400,000 IU, Vitamin E 23gm Vitamin K3 4 gm, Vitamin B1 2 gm, Vitamin B2 5 gm, Vitamin B6 4 gm, Nicotinic Acid 30 gm, Vitamin B12 10 mg, Pantothenic Acid 10 gm, Folic Acid 500 mg, Biotin 50 mg, Cobalt 250 mg,	25kg, 50kg

		Iron 6 gm, Copper 24 gm, Iodine 600 mg, Manganese 50 gm, Zinc 40 gm, Selenium 120 mg, DL-Methionine 50 mg, L-Lysine 30 gm, Carrier (Calcium Carbonate) q.s. to 2.5 kg	
190-19-(16)-010	**AM Broiler Premix**	Each 2.5 Kg Contains: Vitamin A 12,500,000 IU, Vitamin D3 2,500,000 IU, Vitamin E 30 gm, Vitamin k3 4 gm, Vitamin B1 2.5 gm, Vitamin B2 5 gm, Vitamin B6 4 gm, Nicotinic Acid 40 gm, Vitamin B12 12 mg, Pantothenic Acid 12.50 gm, Folic Acid 800 mg, Biotin 400 mg, Cobalt 400 mg, Iron 60 gm, Copper 10 gm, Iodine 400 gm, Manganese 60 gm, Zinc 50 gm, Selenium 150 mg, DL-Methionine 10 gm, L-Lysine 8 gm, Anti-Oxidant 10 gm, Carrier (Calcium Carbonate) q.s. to Kg 2.50	25kg, 50kg
190-19-(16)-011	**AM GS Premix**	Each 2.5 Kg Contains: Vitamin A 12,000,000 IU, Vitamin D3 2500,000 IU, Vitamin E 16 gm, Vitamin k3 2 gm, Vitamin B1 2 gm, Vitamin B2 5 gm, Vitamin B6 3 gm, Nicotinic Acid 25 gm, Pantothenic Acid 12 gm, Vitamin B12 10 gm, Folic Acid 1 gm, Biotin 50 gm, Cobalt 400 mg, Copper 8 gm, Iron 32 gm, Iodine 800 mg, Manganese 60 gm, Zinc 45 gm, Selenium 150 mg, DL-Methionine 50 gm, L-Lysine 30 gm, Carrier (Calcium Bi Carbonate) q.s to 2.5 Kg, Antioxidant 10 gm	25kg, 50kg
190-19-(16)-012	**AM Breeder**	Each 2.5 Kg Contains: Vitamin A 15,500,000 IU, Vitamin D3 3,500,000 IU, Vitamin E 30 gm Vitamin K3 4 gm, Vitamin B1 2.5 gm, Vitamin B2 10 gm, Vitamin B6 5 gm Vitamin B12 15 mg, Nicotinic Acid 40 gm, Pantothenic Acid 15 gm, Folic Acid 1 gm, Biotin 150 mg, Cobalt 500 mg, Iron 40 gm, Copper 10 gm, Iodine 1 gm, Manganese 60 gm, Zinc 80 gm, Selenium 200 mg, DL-Methionine 50 mg, L-Lysine 30 gm, Carrier (Calcium Carbonate) q.s to 2.5 kg, Antioxidant (Ethoxyquin) 10 gm	25kg, 50kg
190-19-(16)-013	**Q-Zyme Plus**	Each gm Contains: Pepsin 50 mg, Pancreatin 100 mg, Lipase 10 mg, Cellulose & concentrated enzyme 20 mg	100gm, 500gm, 1kg
190-19-(16)-014	**AM Toxifree**	Each 10 ml Contains: Calcium Chloride 5 mg, Sodium Selenite 3 mg, Zinc Chloride 2 mg Copper Sulphate 1 mg, Citric Acid 0.5 mg, Phosphoric Acid 5.0 mg, Lactic Acid 0.5 mg a	100ml, 500ml, 1L
190-19-(16)-015	**Amvit ES**	Each ml Contains: Vitamin-E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg	100ml, 500ml, 1L
190-19-(16)-016	**Amvit DB**	Each 1 Kg Contains: Vitamin A 6,000,000 IU, Vitamin D3 20,000 IU, Vitamin E 0.75 gm, Vitamin K3 0.35 gm, Vitamin B1 0.15 gm, Vitamin B2 0.20 gm, Vitamin B6 0.01 gm, Vitamin B12 0.001 gm, Nicotinic Acid 1.25 gm, Pantothenic Acid 0.5 gm, Choline Chloride 25.0 gm, DL-Methionine 10.0 gm	500gm, 1kg, 2kg
190-23-(06)-017	**Calplus Oral**	Each 20 ml Contains: Calcium 325.6 mg, Phosphorus167.7 mg, Magnesium 20 mg, Vitamin B12 20 mcg, Vitamin D3 1600 IU, Sucrose 5 gm, Strawberry Q.S.	500ml, 1L, 5L.

190-23-(06)-018	**Apitazym**	Each 100 gm Contains : Ammonium bicarbonate BP 25.0 gm, Nux Vomica BP 7.0 gm, Sodium bicarbonate BP 65.0 gm, Gentian Powder BP 1.5 gm, Ginger Powder BP 1.5 gm	20gm, 100gm, 500gm, 1kg
190-23-(06)-019	**Acidine PH**	Each Ltr. Contains: Orthophosphoric Acid 0.1575 gm, Propionic Acid 0.01 gm, Acetic Acid 0.25 gm, Lactic Acid 0.1 gm, Citric Acid 0.075gm, Formic Acid 0.030 gm	100ml, 500ml, 1L, 25L.
190-23-(06)-020	**Hycal Plus**	Each 100 gm Contains: Elemental Calcium 4.20 gm, Elemental Phosphorus 1.50 gm, Vitamin C 600 mg, Vitamin D3 40,000 IU, Vitamin B12 1000 Mcg, Citric Acid 27 gm, Excipients qs to 100 gm	500gm, 1kg
190-23-(06)-021	**Zinc M Liquid**	Each 100 ml Contains: Zinc Sulphate Monohydrate 2 gm, & DL-Methionine 0.1 gm	100ml, 500ml, 1L, 5L
190-23-(06)-022	**Alvit-E**	Each ml Contains : Vitamin E Acetate BP 200 mg	100ml, 500ml, 1L
190-23-(06)-023	**Calplus DS Oral**	Each 20ml contains: Calcium 700mg, Phosphorus 350mg, Magnesium 40mg, Vitamin B12 30mcg, Viadim D3 4400IU, Biotin 300mcg, Zinc 10 mg, Copper 4 mg, Carbohydrate 8000 mg, Strawberry q..c .	500ml, 1 lL, 5 L
190-23-(06)-024	**Retivit A**	Each gm contains Vitamin A Acetate BP 10%	100gm, 500gm, 1kg
190-23-(06)-025	**Asvit-C**	Each gm powder contains; Vitamin C (ascorbic acid) 99%	100gm, 500gm, 1kg

Item Code	Items	Composition	Pack Size
190-23-(06)-026	**Bonvit D oral**	Each 100ml contains- Vitamin D3 500000IU, Biotin 1 mg, Propylene Glycol Q.sto. 1 gm	100ml, 500ml, 1L
190-23-(06)-027	**Bovitox Vet**	Each gm powder contains: Calcium Propionate 504 mg, Methionine 40mg, Gentian 0.08 mg, Gluconate 0.32mg, Vitasmin B 6 0.32 mg, Silicon Dioxide 12.8 mg, Excipirnt q.sto 1 gm	125 mg
190-23-(06)-028	**Solomin Oral**	Each ml contains: Phosphorus 2 mg, Manganese 10.087 mg, Iron 9.7 mg, Zinc 10mg, Sodium 5. 5 mg, Cobalt 124 mcg, Copper 5.6 mg, Calcium 15.3 mg	100ml, 500ml, 1L

Imported Finished Products List:

Sl No	Name of imported Products	Brand name of Al-Madina	Name of Country
1	Acidine pH	Acidine PH	Italy
2	Layer premix	Amcom Layer Premix	Italy
3	Aminosol	Amino Sol Liquid	Italy
4	Apsorb	Apsorb	Singapore/Belgium
5	Aqua Richer	Aqua Richer	India
6	Bronchimax	Bronchimax Liquid	Belgium
7	Avipharm ND	Avipharm ND	Slovak Republic
8	Bursipharm	Burshipharm	Slovak Republic
9	Pestipharm B1	Pestipharm B1	Slovak Republic
10	Bronchipharm	Bronchipharm	Slovak Republic
11	BKC Aqua	BKC Aqua	India
12	Calpro D +	Calpro D +	India
13	Choline Chloride	Choline Choride	China
14	DCP	DCP	China
15	MCP	MCP	China
16	DL-Methonine	DL-Methonine	Germany/China
17	Good Cleaner	Good Cleaner	S. Korea
18	Gaspel	Gaspel Powder	India
19	Gutbac	Gutbac	India
20	Hepaton	Hepaton Liquid	Italy
21	Hyvit ADE	Hyvit ADE Liquid	Singapore/Belgium
22	Hyvit DB	Hyvit DB Powder	Belgium
23	Hyvit ES Plus	Hyvit - ES Plus	Singapore/Belgium
24	Hyvit Fort WS	Hyvit Fort WS Powder	Singapore/Belgium
25	Immunity stim	Immunity Stim Liquid	Italy
26	Polgro	Polgro	India
27	Livtor	Livtor Liquid	India
28	L-Threonine	L-Threonine	China
29	L-Lysine	L-Lysine	China
30	Madina Zeo	Madina Zeo	Indonesia
31	Mould Fix	Mould Fix	Singapore/Belgium
32	Multimixzyme	Multimixzyme	Germany
33	Nephro - Guard	Nephro- Guard	India
34	NL 100 Fat	NL 100 Fat	Malaysia
35	Nu3link Xls	Nu3link Xls	Belgium
36	Nu3phos	Nu3phos	Belgium
37	Pure - Oxy Powder	Pure - Oxy Powder	China
38	Pure - Oxy Tablet	Pure - Oxy Tablet	China
39	Pure-Yucca	Pure-Yucca	India
40	Q-Zyme Plus Powder	Q-Zyme Plus Powder	India
41	Salmokil	Salmokil	Singapore/Belgium
42	Toxifree Liquid	Toxifree Liquid	India
43	Toxin Binder	Toxin Binder	Singapore/China

Sl No	Name of imported Products	Brand name of Al-Madina	Name of Country
44	Grozyme WSP	Grozyme WSP	India
45	Nicoli WSP	Nicoli WSP	India
46	Niltox Liquid	Niltox Liquid	India
47	Gropti-Z Liquid	Gropti-Z Liquid	India
48	Liverguard +	Liverguard +	India
49	Zenotox Powder	Zenotox Powder	India
50	M-kolin Powder	M-kolin Powder	India
51	Viru check	Viru check	India
52	Antimast Powder	Antimast Powder	India
53	Bovipro Bolus	Bovipro Bolus	India
54	Orioil	Orioil	India
55	Panavis Oral solution	Panavis Oral solution	India
56	Diacell R	Diacell R	India
57	Norgain powder	Norgain powder	India
58	Bictoria	Bictoria	Netherland

Striving for Excellence



Product List
Human Division:

Sl. No.	Products Name	Generic Name with Strength	Dosages Form
1	**Amiphin 1 gm IV Injection**	Sterile Ceftriaxone Sodium USP 1.19 gm eqv. to Ceftriaxone 1 gm	Injection
2	**Amiphin 2 gm IV Injection**	Sterile Ceftriaxone Sodium USP 2.38 gm eqv. to Ceftriaxone 2 gm	Injection
3	**Cipex 250 Tablet**	Ciprofloxacin Hydrochloride USP 291.106 mg eqv.to Ciprofloxacin 250 mg	Capsule
4	**Cipex 500 Tablet**	Ciprofloxacin Hydrochloride USP 582.212 mg eqv.to Ciprofloxacin 500.00 mg	Tablet
5	**Cipex 750 Tablet**	Ciprofloxacin Hydrochloride USP 873.318 mg eqv. to 750mg Ciprofloxacin	Tablet
6	**Cipex PFS**	Ciprofloxacin 20% Pellets /Granules Pharma Grade 25gm eqv. to Ciprofloxacin 5gm/100ml	PFS
7	**Claviator-CV 250 Tablet**	Cefuroxime (as Cefuroxime Axetil USP) 250 mg + Clavulanic Acid (as Potassium Clavulanate BP) 62.50 mg	Tablet
8	**Claviator-CV 500 Tablet**	Cefuroxime (as Cefuroxime Axetil USP) 500 mg + Clavulanic Acid (as Potassium Clavulanate BP) 125 mg	Tablet

Sl. No.	Products Name	Generic Name with Strength	Dosages Form
9	**Claviator -CV PFS**	Cefuroxime USP 125 mg + Clavulanic Acid 31.25 mg/5 ml Powder For Suspension	PFS
10	**Isovox 500 Tablet**	Levofloxacin Hemihydrate USP 512.469 mg eqv. to Levofloxacin 500 mg	Tablet
11	**Prex-3 200 Capsule**	Cefixime (as Cefixime Trihydrate USP) 200 mg	Capsule
12	**Prex-3 400 Capsule**	Cefixime (as Cefixime Trihydrate USP) 400 mg	Capsule
13	**Prex-3 PFS**	Cefixime (as Cefixime Trihydrate USP) 100 mg/5ml	PFS
14	**Thoraz 250 Tablet**	Azithromycin Dihydrate USP 262.015 mg eqv.to Azithromycin 250 mg	Tablet
15	**Thoraz 500 Tablet**	Azithromycin Dihydrate USP 524.03 mg eqv.to Azithromycin 500 mg	Tablet
16	**Thoraz PFS**	Azithromycin 7.5% bitter less Powder (Ready Mix) Pharma grade 53.333 gm, eqv.to Azithromycin 4 gm	PFS
17	**Topflu 500 Capsule**	Flucloxacillin Sodium BP 549.44mg eqv.to Flucloxacillin 500 mg Capsule	Capsule
18	**Topflu PFS**	Flucloxacillin Sodium BP 139.4mg eqv.to Flucloxacillin 125 mg/5 ml PFS	PFS
19	**Flumazole 150 Capsule**	Fluconazole USP 150mg	Capsule
20	**Flumazole 50 Capsule**	Fluconazole USP 50 mg	Capsule
21	**Micoheal Oral Gel**	Miconazole BP 20mg	Gel
22	**Terbiheal Tablet**	Terbinafine Hydrochloride USP 281.3 mg eqv. to Terbinafine 250 mg	Tablet

Analgesic, Antipyretic & Skeletal Muscle Relaxant

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Ampol 500 Tablet**	Paracetamol BP 500mg	PFS
2	**Ampol Plus Tablet**	Paracetamol BP 500mg + Caffeine Anhydrous BP 65mg	Tablet
3	**Ampol XR Tablet**	Paracetamol BP 665 mg	Tablet
4	**Anaprox Tablet**	Esomeprazole Magnesium Trihydrate USP 23.88 mg eqv.to Esomeprazole 20 mg + Naproxen BP 500mg	Tablet
5	**Claim 100 Tablet**	Aceclofenac BP 100mg	Tablet
6	**Claim ER Tablet**	Aceclofenac BP 200mg	Tablet
7	**Coxtop 120 Tablet**	Etoricoxib INN 120mg	Tablet
8	**Coxtop 60 Tablet**	Etoricoxib INN 60mg	Tablet
9	**Coxtop 90 Tablet**	Etoricoxib INN 90mg	Tablet
10	**Diclofast SR Capsule**	Diclofenac Sodium SR pellets 40 % w/w Pharma Grade 250 mg eqv. to Diclofenac Sodium BP 100 mg	Capsule

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
11	**Tufexil Tablet**	Tolfenamic Acid BP 200mg	Tablet
12	**Xiroket IM/IV Injection**	Ketorolac Tromethamine USP 30 mg	Injection
13	**Xiroket 10 Tablet**	Ketorolac Tromethamine USP 10 mg	Tablet
14	**Xiroket IM/IV Injection**	Ketorolac Tromethamine USP 60 mg/2ml	Injection
15	**Zerofen 100 ablet**	Ketoprofen BP 100mg	Tablet
16	**Zerolent 10 Tablet**	Baclofen USP 10 mg	Tablet

Anti-Histamine, Bronchodilator & Leucotrine Receptor Antagonist

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Cetmax 10 Tablet**	Cetirizine Dihydrochloride BP 10mg	Tablet
2	**Rynofex 120 Tablet**	Fexofenadine HCl USP 120 mg	Tablet
3	**Rynofex 180 Tablet**	Fexofenadine HCl USP 180 mg	Tablet
4	**Ventilast 10 Tablet**	Montelukast Sodium USP 10.40 mg eqv. to Montelukast 10 mg	Tablet
5	**Freeway 200 Tablet**	Doxophylline INN 200 mg	Tablet
6	**Freeway 400Tablet**	Doxophylline INN 400 mg	Tablet

Anti - Ulcerant, Gastroprokinetic & Anti-Spasmodic

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Gastrozole 20 Tablet**	Rabeprazole Sodium INN 20mg	Tablet
2	**Prilosec 20 Tablet**	Pantoprazole Sodium Sesquihydrate BP 22.55 mg eqv. to Pantoprazole 20 mg	Tablet
3	**Prilosec 40 Tablet**	Pantoprazole Sodium Sesquihydrate BP 45.10 mg eqv. to Pantoprazole 40 mg	Tablet
4	**Raceper 20 Capsule**	Esomeprazole Magnesium Trihydrate enteric coated pellets 8.5% Pharma Grade 235.294 mg eqv. to Esomeprazole 20 mg	Capsule
5	**Raceper 20 Tablet**	Esomeprazole Magnesium Trihydrate USP 23.88 mg eqv. to Esomeprazole 20 mg	Tablet
6	**Raceper 40 Capsule**	Esomeprazole Magnesium Trihydrate enteric coated pellets 8.5% Pharma Grade 470.588 mg eqv. to Esomeprazole 40 mg	Capsule
7	**Zolat 20 Capsule**	Omeprazole enteric coated pellets 8.5% Pharma Grade 235.294 mg, eqv. to Omeprazole BP 20 mg	Capsule
8	**Zolat 40 Capsule**	Omeprazole enteric coated pellets 8.5% Pharma Grade 470.588 mg eqv. to Omeprazole BP 40.00 mg	Capsule
9	**Almigut Tablet**	Domperidone Maleate BP 12.72 mg eqv. to Domperidone 10 mg	Tablet
10	**Freespa 50 Tablet**	Tiemonium Methyl Sulphate INN 50mg	Tablet

Vitamin & Minerals

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Alovit BZ Tablet**	Zinc Sulphate Monohydrate BP 27.45mg eqv. to Elemental Zinc 10 mg + Thiamine Mononitrate (B1) BP 5mg + Riboflavin (B2) BP 2.75mg + Pyridoxine HCI (B6) BP 2mg + Nicotinamide (B3) BP 20 mg	Tablet
2	**Alovit Gold Tablet**	Multivitamin & Multimineral	Tablet
3	**Alovit-C 250 Chewable Tablet**	Ascorbic Acid BP 100mg + Sodium Ascorbate BP 168.75 mg eqv. to Ascorbic Acid 150mg	Tablet
4	**B3 Tablet**	Thiamine Mononitrate USP 100 mg + Pyridoxine Hydrochloride BP 200 mg + Cyanocobalamin BP 200 mcg	Tablet
5	**Bonwell-D Tablet**	Calcium Carbonate BP 1250 mg eqv. to elemental Calcium 500 mg + Vitamin D3 BP 200IU	Tablet
6	**Carbium Capsule**	Carbonyl Iron, Zinc , Vitamin B Complex, Folic Acid and Vitamin C Blended Pellets Pharma Grade 440mg	Tablet
7	**Coralium -D Tablet**	Calcium Carbonate (Coral Calcium) BP 1250 mg eqv.to elemental Calcium 500mg + Vitamin D3 BP 200 IU	Tablet
8	**Zinc Kid Dispersible Tablet**	Zinc Sulfate Monohydrate BP 54.90 mg eqv. to elemental Zinc 20mg	Tablet

Antiepileptic

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Algaba 50 Capsule**	Pregabalin INN 50mg	Capsule
2	**Algaba 75 Capsule**	Pregabalin INN 75mg	Capsule
3	**Algaba 150 Capsule**	Pregabalin INN 150mg	Capsule

Lipid Lowering Agent, Fibrates & Anti-Hypertensive

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Atomax 10 Tablet**	Atorvastatin Calcium Trihydrate USP 10.85 mg eqv. to Atorvastatin 10 mg	Tablet
2	**Atomax 20 Tablet**	Atorvastatin Calcium Trihydrate USP 21.7 mg eqv. to Atorvastatin 20 mg	Tablet
3	**BC-Card Tablet**	Amlodipine Besilate BP 694mg eqv. to Amlodipine 5 mg + Atenolol BP 50mg	Tablet
4	**Fenogard 200 Capsule**	Fenofibrate (micronised) BP 200mg	Capsule

Antidiabetic

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Diabest 500**	Metformin HCl BP 500 mg	Tablet

Anxiolytic & Antidepressant

Sl. No.	Brand Name	Generic Name with Strength	Dosages Form
1	**Fulrest Tablet**	Flupentixol Dihydrochloride BP 584 mcg eqv. to Flupentixol 500 mcg + Melitracen Hydrochloride INN 11.25 mg eqv. to Melitracen 10 mg	Tablet

Antihelminthic

Sl. No.	Brand Name	Generic Name with Strength	Pack Size
1	**ABZ 400 Chewable Tablet**	Albendazole USP 400mg	100's

Urinary Alkalizing Agent / Urinary Retention

Sl. No.	Brand Name	Generic Name with Strength	Pack Size
1	**Alken Solution**	Potassium Citrate BP 30 gm + Citric Acid Monohydrate BP 5gm/100ml	Oral Solution
2	**Uripay 100 Tablet**	Flavoxate Hydrochloride BP 100 mg	Tablet
3	**Uripay 200 Tablet**	Flavoxate Hydrochloride BP 200 mg	Tablet
4	**Urivent Capsule**	Tamsulosin Hydrochloride SR pellets 0.2% Pharma Grade 200 mg eqv. toTamsulosin Hydrochloride 0.4mg	Capsule

Topical Preparation

Sl. No.	Brand Name	Generic Name with Strength	Dosage Form
1	**Alivio Cream**	Methyl Salicylate BP 150mg + Menthol BP 100mg	Cream
2	**Alivio Extra Cream**	Camphor USP 4g + Menthol BP 10g + Methyl Salicylate 30g/100g	Cream
3	**Spotless Cream**	Hydroquinone USP 40mg	Cream
4	**Terbiheal Cream**	Terbinafine Hydrochloride USP 11.25 mg eqv. to Terbinafine 10 mg	Cream
4	**Miaz Cream**	Miconazole Nitrate BP 20mg	Cream

Hand Sanitizing Preparation

Sl. No.	Brand Name	Generic Name with Strength	Dosage Form
1	**Cleanex Hand Sanitizer Gel**	Ethyl Alcohol BP 66ml + lsopropyl Alcohol BP 3.5ml/100ml	Hand Sanitizer
2	**Hexil Hand Sanitizer**	lsopropyl Alcohol (99.80%) BP 75.15 ml +Hydrogen peroxide (3%) BP 4.17ml + Glycerol (98%) BP 1.45ml	Hand Sanitizer

Upcoming new Product list (As per future planning):

Agro vet Division:

Sl. No.	Brand Name	Generic Name with Strength	Pack Size
1	**Marboquin DS Bolus (Vet)**	Each bolus contains Marbofloxacin BP 100mg	3x4's, 5x4's, 10x4's
2	**Tracemin Bolus (Vet)**	Each bolus contains Copper Sulphate Pentahydrate BP 100mg, Cobalt Sulphate Heptahydrate INN 4 mg, Manganese Sulphate Monohydrate USP 50mg, Zinc Sulphate Monohydrate BP 300 mg, Potassium Iodide USP 5mg, Dried Ferrous Sulphate BP 100 mg, Sodium Selenite BP 1 mg	5x2's, 10x2's, 20x2's
3	**Marboquin Oral Solution (Vet)** **NS-70 Vet Powder**	Each 100ml contains Marbofloxacin BP 10 gm Neomycin Sulfate BP 700mg/gm	15ml, 100ml, 500ml 100gm, 500gm, 1kg
4	**Ceftifur Vet 0.5gm**	Ceftiofur Sodium USP 0.532 gm eqv. To Ceftiofur 0.500 gm/vial Injection (vet)	0.5 gm vial
5	**Ceftifur Vet 1gm**	Ceftiofur Sodium USP 1.064 gm eqv. To Ceftiofur 1 gm/vial Injection (vet)	1.00 gm vial
6	**Cefam Vet 1gm**	Ceftriaxone Sodium USP 1.19 gm eqv. To Ceftriaxone 1 gm/vial Injection (vet)	1.00 gm vial
7	**Cefam Vet 2 gm**	Ceftriaxone Sodium USP 2.38 gm eqv. To Ceftriaxone 2 gm/vial Injection (vet)	2 gm vial
8	**Calmolin-Vet Powder**	Amoxicillin Trihydrate BP 100mg+ Diluted Potassium Clavulanate BP 50mg eqv. To Potassium Clavulanate 25 mg/gm Powder (Vet)	100gm, 500gm, 1kg
9	**Not yet selected**	Ivermectin BP 200 mg+ Triclabendazole BP 12 gm/ 100ml Suspension (Vet)	10ml, 50ml, 100ml
10	**Not yet selected**	Flunixin Meglumine USP 830mg eqv. To Flunixin 500 mg/10ml injection	

Human Division:

Sl. No.	Product Name	Dosage Form
1	Amiphin 500 I IV (Ceftriazone USP 500 mg)	Injection
2	SuperBug 1 gm IV (Meropenem USP 1gm)	Injection
3	Dexobest INN 30 mg (Dexlansoprazole INN 30 mg)	Capsule
4	Dexobest INN 60 mg (Dexlansoprazole INN 60mg)	Capsule
5	Fexofenadine Hydrochloride USP 30mg/5ml	PFS
6	Itraconazole USP 100 mg	Capsule
7	Sodium Alginate BP 5GM+ Sodium Bicarbonate BP 2.67 gm +Calcium Carbonate BP 1.60gm/100 ml	Syrup
8	Ketotifen Fumarate BP 1.380 mg eqv. To Ketotifen 1 mg/5ml	Syrup
9	Zinc Sulphate Monohydrate USP 27.44 mg eqv.Elemental Zinc 10mg/5ml	Syrup
10	Butamirate Citrate INN 7.5 mg/5ml	Syrup

Sl. No.	Product Name	Dosage Form
11	Ambroxol HCl BP 15 mg/5ml	Syrup
12	Cetirizine Dihydrochloride BP 5mg/5ml	Syrup
13	Guaifensin BP 100mg, Levomenthol BP 1.1 mg and Diphenylhydramine Hydrochloride BP 14 mg/5ml	Syrup
14	Dextromethorphan Hydrobromide 6.5 mg+Levomenthol 2 mg+Diphenhydramine Hydrochloride 14 mg/5ml	Syrup
15	Domperidone BP 5mg/5ml	Suspension
16	Clotrimazole BP 10mg/gm	Cream
17	Econazole Nitrate BP 10mg/gm	Cream
18	Econazole Nitrate BP 10mg/gm +Triamcinolone Acetonide BP 1 mg/gm	Cream
19	Montelukast Sodium USP 5.20 mg eqv. To Montelukast 5 mg	Tablet
20	Moxifloxacin USP 400mg	Tablet
21	Rupatadine BP 10 mg	Tablet
22	Bilastine INN 20 mg	Tablet
23	Ondansetron HCl Dihydrate USP 9.976 mg eqv. To Ondansetron 8 mg	Tablet
24	Sodium Picosulfate BP 10 mg	Tablet
25	Calcium Carbonate (Algae Source) 1250 mg eqv. To Elemental Calcium USP 500 mg+Vitamin D3 USP 200 IU	Tablet
26	Vildagliptin INN 50 mg	Tablet
27	Diabest 850 mg (Metformin HCl BP 850 mg)	Tablet
28	Alzide (Gliclazide BP 80 mg)	Tablet
29	Linatop (Linagliptin INN 5 mg)	Tablet

Export in Process of Pharma Product:

Al-Madina Pharmaceuticals Ltd is producing good quality products for human health servicing. We have good at management, sophisticated technology, well set up laboratory etc. We are following all compliance for operation of factory and development of products.. We have completed export amount of taka 1.54 Core during the year 2024-2025.We are trying to do more export of Pharma products upcoming years. At this moment, we have two buyers Hejaz Ltd, Afghanistan and Al-Zubaidi Stores, Yemen. We are doing Export the following products.

Sl. No	Brand name	Generic Name	Pack Size	Dosage Form
1	Almight	Domperidone Malcate BP12.72 mg cqv.to Domperidone 10mg	100s	Tablet
2	Alovit BZ Tab	Zinc Sulphate Monohydrate BP 27.45mg Eqv. to Elemental Zinc 10mg + Thiamine Mononitrate (B1)BP 5mg +Riboflavin (B2) BP2.75mg + Pyridoxine HCI (B6) BP 2mg +Nicotinamide (B3)BP20 mg	30s	Tablet
3	Ampol 500 Tab	Paracetamol BP 500mg	300s	Tablet
4	Ampol Plus Tablet	Paracetamol BP 500mg+ Caffeine Anhydrous BP65mg	200s	Tablet
5	Bonwell D	Calcium Carbonate BP 1250 mg eqv. To elemental Calcium 500mg+Vitamin D3 BP 200IU	15s	Tablet
6	Bonwell D	Calcium Carbonate BP 1250 mg eqv. To elemental Calcium 500mg+Vitamin D3 BP 200IU	30s	Tablet
7	Fulrest Tab	Flupentixol 500Mg +Melitracen 10 mg	100s	Tablet

Sl. No	Brand name	Generic Name	Pack Size	Dosage Form
8	Prex-3	Cefixime (As Cefixime Trihydrate USP) 100mg/5ml	30ml	PFS
9	B3	Thiamine Mononitrate 100mg +Pyridaxine Hydrochloride 200 mg + Cyanocobaiamine 200 mcg	60s	Tablet
10	ventilast 10	Montelukast 10 mg	30s	Tablet
11	Thoraz 500	Azithromyon 500mg	12s	Tablet
12	Rynofex 120	Fexofenadine HCI 120 mg	50s	Tablet
13	Rynofex 180	Fexofenadine HCI 180 mg	30s	Tablet
14	ABZ 400 Chewable	Albendazole 400mg	50s	Tablet

Product Performance based on Sales:

Top Ten Products list:

Agro vet Division:

1. NS-Vet Powder
2. Tilvet Liquid
3. Set-3 Powder
4. Alcipro-vet Solution
5. Anticocci-K Powder
6. T-Zuril Liquid Vet
7. Aminosol Liquid
8. LV-Vet Powder
9. Alenro Vet Solution
10. FC-Vet Oral Solution



Human Division:

1 Zolat 20 Capsule
2 Thoraz 500 Tablet
3 Raceper 20 Capsule
4 Claviator-CV 250 Tablet
5 Anaprox Tablet
6 B3 Tablet
7 Prex-3 200 Capsule
8 Tufexil
9 Ventilast 10 Tablet
10 Coralium-D 30's Tablet



Extra –Ordinary gain or Loss:

There is no Extra –Ordinary gain or loss during the year which require adjustment or disclosure in the financial statement.

Related Party Transaction:

During the year under audit the company carried out no transaction with related parties in normal course of business. It is disclosed in the notes no 32.02 to the financial statements for the year ended 30.06.2025 as short term employee benefits.

Utilization of proceeds through QIO:

Al-Madina Pharmaceuticals Ltd has raised Capital tk 5.00 Core through QIO .The utilization of proceed for raising Capital through QIO as at. 31.05.2025 has Given Company Website Link :https://almadinapharma.com.

Remuneration of Directors:

This information is incorporated in the notes No 32.02 to the financial statement.

Capacity Utilization:

The overall capacity utilization of the plant operation during the year 2024-2025 has been presented hereun- der:

Types of Machine	Unit	Installed Capacity per annum (291 working day/single shift)	Actual Production per annum	% of capacity utilization
Tablet	Pcs	436500000	22,69,80,000	52
Capsule	Pcs	167616000	8,04,55,680	48
Liquid	Liter	291000	1,51,320	52
Liquid (Externa l)	Bottle	2328000	1,86,240	8
Powder	kg	145500	80,025	55
Bolus	Pcs	29100000	1,39,68,000	48
Semisold (cream, ointment, gel)	Tube	2328000	14,43,360	62
PFS	Bottle	2328000	3,25,920	35

Industry outlook and possible future development in the industry:

Pharmaceutical industry is one of the most promising sectors in Bangladesh. After the promulgation of local industry friendly Drug (Control) Ordinance in 1982 the scenario of pharmaceutical industries changed considerably. Now, after fulfilling the local demand, Bangladesh is exporting pharmaceutical products to over 100 countries of the world. There are still lots of space for Bangladesh to flourish in this sector. So, initiatives from the stakeholders are required to ensure the remarkable growth of pharmaceutical industries in Bangladesh. The pharmaceuticals industry of Bangladesh is driving to change by increasing per capita income, population growth, changing disease profile, lifestyle changed and rapid urbanization.

Financial Result (5 Years):

The Financial Result of the Company is hereunder:
Five Years Financial Information:
Revenue and Results from Operation:

Particulars	30.06.2025	30.06.2024	30.06.2023	30.06.2022	30.06.2021
Sales Revenue	481,684,250	644,127,729	685,624,856	**668,965,108**	**556,164,433**
Cost of Goods Sold	(260,170,983)	(351,993,106)	(404,897,888)	(398,296,705)	(350,825,289)
Gross Profit	221,513,267	292,134,623	280,726,968	**270,668,403**	**205,339,144**
Administrative & General Expenses	25,130,065	(32,506,911)	(32,783,093)	(35,512,458)	(29,353,052)
Marketing, Selling & Distribution Expenses	160,548,532	(214,887,306)	(199,671,749)	(188,954,187)	(132,404,722)
Operating Profit	35,834,670	44,740,406	48,272,126	46,201,758	43,581,370
Financial Expenses	19,483,968	18,115,421	14,515,647	(12,321,155)	(12,808,039)
Net Profit/(Loss) for the year Before WPPF	16,350,702	26,624,985	33,756,479	33,880,603	30,773,331
Workers' Profits Participation Funds	778,605	(1,267,856)	(1,607,451)	(1,613,362)	(1,465,397)
Net Profit/(Loss) before Tax	15,572,097	25,357,129	32,149,027	32,267,241	29,307,934
Current tax	7,295,203	(6,595,038)	(5,897,504)	(9,680,172)	(8,792,380)
Deferred tax Income/(Expenses)	(3,598,832)	(934,194)	(1,085,353)	(2,848,529)	2,672,783
Net Profit/(Loss) after Income Tax	11,875,726	17,827,897	25,166,171	19,738,540	23,188,337
Other Comprehensive Income:				-	138,967,050
Revaluation Reserve				-	143,265,000
Less: Deferred Tax Liabilities on Revaluation Reserve				-	(4,297,950)
Total Comprehensive Income	11,875,726	17,827,897	25,166,171	19,738,540	162,155,387
Earnings Per Share Basic	0.58	0.87	1.57	1.30	33.99

Statement of Financial Position:

Particulars	30.06.2024	30.06.2024	30.06.2023	30.06.2022	30.06.2021
ASSETS					
Non-Current Assets	306,986,090	308,873,618	317,176,332	333,166,382	328,029,470
Property Plant and Equipment	295,435,685	296,039,834	299,895,672	317,322,205	315,447,070
Right-of- Use Asset (ROU)	11,550,405	12,833,784	14,259,760	15,844,178	12,582,400
Current Assets	278,888,951	314,513,316	322,700,893	214,101,090	144,709,219
Inventories	24,573,310	24,255,210	26,313,770	24,411,720	22,550,762
Inventory In Transit	0	6,428,256	3,277,085	3,133,256	1,592,498
Deferred Tax asset	0				3,742,186
Accounts and other Receivable Advance Deposit &	211,252,592	201,164,450	214,863,981	144,589,522	85,044,266
Pre-Payments	37.245,674	32,434,263	36,030,322	25,345,244	19,781,797
Cash and Bank Balances	5,817,374	50,231,137	42,215,736	16,621,348	11,997,710
TOTAL ASSETS	**585,875,041**	**623,386,934**	**639,877,225**	**547,267,472**	**472,738,689**
EQUITY AND LIABILITIES					
Equity attributable to the owners of the company	420,442,619	415,946,893	404,268,996	333,400,775	287,662,235
Share Capital	204,000,000	204,000,000	204,000,000	154,000,000	128,000,000
Retained Earnings	77,475,569	72,979,843	61,301,946	43,850,085	20,695,185
Revaluation Reserve	138,967,050	138,967,050	138,967,050	138,967,050	138,967,050
Non-Current Liabilities	6,372,638	14,967,974	15,589,991	15,257,539	16,412,304
Long Term Loan from Bank	249,680	3,697,968	4,564,509	7874546	6,811,491
Deferred Tax Liabilities	6,122,958	9,721,790	8,787,596	3,404,293	4,297,950
Lease obligation (non-Current)	0	1,548,216	2,237,886	3,978,700	5,302,863
Current Liabilities & Provisions	159,059,784	192,472,068	220,018,240	198,609,159	168,664,150
Long Term Loan (Current Portion)	3,294,066	2,666,500	3,310,037	1,284,461	
Lease obligation (Current)	0	1,155,369	1,866,003	3,671,146	4,711,968
Short Term Loan	106,136,678	140,447,626	163,348,334	148,909,450	132,327,788
Accounts Payable	4,130,200	3,510,400	3,840,445	3,145,000	3,565,560
Liabilities for Expenses	21,506,219	21,399,718	21,911,378	21,754,562	17,894,467
Provision for income tax	23,992,620	23,292,455	25,742,043	19,844,539	10,164,367
TOTAL SHAREHOLDERS'					
EQUITY AND LIABILITIES	585,875,041	623,386,934	639,877,225	547,267,472	472,738,689
Net Asset Value Per Share with Revaluation	20.61	20.39	19.82	21.65	22.47
Net Asset Value Per Share without Revaluation	13.80	13.58	13.00	12.63	11.62

Statement of Cash Flows:

Particulars	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
A. Cash Flow from Operating Activities	**19,204,398**	**51,039,132**	**(26,323,262)**	**(8,401,604)**	**44,973,738**
Cash from Customer	471,596,108	657,827,260	615,350,397	678,556,692	539,887,970
Cash paid to Suppliers,Employee and other Expenses	(452,391,709)	(600,193,089)	(632,629,033)	(68,0743,955)	(494,914,232)
Tax Paid	0	(6,595,038)	(9,044,626)	(6214341)	
B. Cash Flow from Investment Activities	**(16,402,908)**	**(11,062,642)**	**(7,690,815)**	**(24,516,710)**	**(68,871,538)**
Cash for Property ,Plant and Equipment	(16,402,908)	(11,062,642)	(2,690,815)	(24,516,710)	(68,871,538)
Paid for Building Construction work in Progress			(5000000)	-	-
C. Cash Flow from Financing Activities	(47,215,253)	(31,961,090)	59,608,466	37,541,951	22,464,836
Cash for Long Term Liabilities	(2,820,722)	(1,510,078)	(1,284,461)	2,347,516	(3,532,487)
Divident Paid	(7,380,000)	(6,150,000)			
Lease obligation	(2,703,585)	(1,400,304)	(3545957	(7,387,227)	(5,713,169)
Cash for Short Term Liabilities	(34,310,948)	(22,900,708)	14,438,884	16,581,662	11,710,492
Share Capital	0		50,000,000	26,000,000	40,000,000
Share Money	0		-	-	(20,000,000)
D.Net cash flow for the year (A+B+C)	**(44,413,763)**	**8,015,400**	**25,594,389**	**4,623,638**	**(1,432,964)**
E. Opening Cash and Cash Equivalents	**50,231,137**	**42,215,736**	**16,621,348**	**11,997,710**	**13,430,674**
F. Closing Cash and Cash Equivalents	**5,817,374**	**50,231,137**	**42,215,736**	**16,621,348**	**11,997,710**

Significant Information:

The significant information of the financial statements are stated as below:

Sl No.	Particulars	Year ended on 30 June 2025	Year ended on 30 June 2024
I	Earning per share (EPS)-Basic/Weighted average	0.58	0.87
II	Earning per share (EPS)- Diluted	0.58	0.87
III	Net Asset Value (NAV) with Revaluation	42,04,42,619	415,946,893
iv	Net Asset Value (NAV) without Revaluation	28,14,75,569	276,979,843
v	NAV per share with revaluation	20.61	20.39
vi	NAV per share without revaluation	13.80	13.58
vii	Net Operating Cash Flow per share (NOCFPS)	0.94	2.50

"The details of the financial statements is available in the website https0://almadinapharma.com"

Environmental Rule:
The Company maintains a high standard of pollution free environment as per GMP Regulations/Who/ Government Laws.

Quality Rule:
The Company maintains a high quality management as per ISO 9001- 2015 Rules.

Credit Rating:
The ALFA has confirmed the credit rating for long term rating A- and for short term rating ST-2 on the basis of financial report as at 30.06.2024 and other relevant qualitative and quantitative information of the company.

Compliance of Financial Statement:
The financial statements have been meticulously prepared to adhere to the stipulations set forth by the Companies Act of 1994, the Securities and Exchange Rules of 2020, The Value Added Tax and Supplementary Duty Act, 2012, the Income Tax Act 2023 and pertinent local regulations. Furthermore, these statements have been designed in accordance with the guidelines of the International Financial Reporting Standard (IFRS) and the International Accounting Standards (IAS). These statements present fairly the company's state of affairs, the result of Operation, Cash flow and changes in equity.

Proper Books of Accounts:
Books of Accounts of the company have been maintained properly.

Accounting Policies:
The accounting principles and policies pertaining to significant components of the financial statements, as detailed below, have been consistently employed across all periods presented within these financial statements.

Presentation of Financial Statement:
The financial statements has provided according to the guidelines of IAS 1: Presentation of Financial Statements.

These financial statements consist of the following components:
(a) Statement of Financial Position as at June 30, 2025.
(b) Statement of Profit or Loss and Other Comprehensive Income for the period from July 1, 2024, to June 30, 2025.
(c) Statement of Changes in Shareholders' Equity for the period from July 1, 2024, to June 30, 2025.
(d) Statement of Cash Flows for the period from July 1, 2024, to June 30, 2025.
(e) Statement of Notes, which includes a summary of significant accounting policies and explanatory information.

Internal Control:
The internal Control System of Al-Madina Pharmaceuticals Ltd has been designed to save the risk, material loss, accountability and record transaction properly. The board is reviewing its effectiveness in accordingly.Loss, Accountability and record transaction properly. The board is reviewing its effective ness in accordingly.

Minority Shareholders Interest:
The Board hereby confirmed that the interest of minority shareholders has been fully protected in the company.

Going Concern:
The presented financial statements have been formulated with consideration of the company's ability to oper- ate as a going concern. In light of this, the board of directors persists in utilizing the going concern concept for the preparation of the financial statements. At present, the company's existing resources and credit arrange- ments are deemed satisfactory to fulfill the immediate needs of its ongoing business activities.

Significant deviation from the last years operating result:

Significant variations over the last year's operation of the company have been made due to excess expenditure incurred in the administrative and general expenses, selling and distribution expenses and reduce expenditure incurred in the factory overhead. The positive impact of excess and reduce expenditure is gradually taking place

Declaration of dividend:

The Board of directors is pleased to recommend a cash dividend @ 12% only for shareholders and 1% for sponsors or directors for financial year 2024-2025 based on the performance of the company. The recommend dividend is stated bellow as at 6.10.2025:

Name of Shareholders	No of Share	Dividend-BDT	Remarks
Directors and Sponsors	1,42,50,000	14,25.000	
General shareholders	61,50,000	73,80,000	
Total	2,04,00,000	88,05,000	

Directors:

The name of Directors of the Company and their positions are shown on the following table:

Name of Directors	Position
Md. Billal Hossain	Chairman
Mohammad Zakir Hossain Patowary	Managing Director
Md. Kamrul Alam	Director

Re-election of Directors:

Mr Md Kamrul Alam retires under Article 57 of the article of Association of the Company. Mr. Md. Kamrul Alam eligible and offered himself for re-election. The board recommends his re-appointment.

Appointment of Statutory Auditors:

The Audit of the company for the year ended 30 June 2025 has been carried by the Auditors of the company Anil Salam Idris & Co. Chartered Accountants. The new auditor Ahsan Manzur & Co., Chartered Accountants is eligible for appointment. According the board of directors has recommended to appoint new auditor Ahsan Manzur & Co. Chartered Accountants. Audit fees will be determined as per ICAB Guideline.

Pattern of Shareholders:

Name	Designation	% of Shares		No. of Share	
		30-06-2024	30-06-2025	30-06-2024	30-06-2025
Directors					
MD. Billal Hossain	Chairman	20.96%	20.96%	4,275,000	4,275,000
MD. Zakir Hossain Patwary	Managing Director	31.43%	31.43%	6,412,500	6,412,500
MD. Kamrul Alam	Director	17.46%	17.46%	3,562,500	3,562,500
Total		69.85%	69.85%	14,250,000	14,250,000
Others					
General shareholders		30.15%	30.15%	6,150,000	6150000
Total		30.15%	30.15%	6,150,000	6150,000
Grant Total		100.0%	100.0%	20,400,000	20,400,000

Dividend Policy:

i. The profit of the Company, subject to any special right relating thereto created or authorized to be created by the Memorandum and subject to the provisions of the Articles of Association, shall be divisible among the members in proportion to the amount of capital paid-up on the shares held by them respectively.

ii. The dividend shall be recommended by the Board of Directors time to time for distributing the accumulated profit.

iii. No dividend shall be payable except out of the profits of the Company or any other undistributed profits. The dividend shall not carry interest as against the Company.

iv. The Directors may from time to time pay the members such interim dividend as in their judgment the financial position of the Company may justify.

v. A transfer of shares shall not pass the right to any dividend declared thereon before the registration of transfer.

vi. The Company shall maintain all rules and compliance of DSE, CSE and BSEC on the subject of Dividend.

vii. No limitation in payment of the dividend is stipulated in any debt instrument or otherwise,

Legal and Other Information:

Sl.	Description of Certificate/ License/Registration	License Issuer/Issuing Authority
1	Certificate of Incorporation	Registrar of Joint Stock Companies & Firms, Bangladesh (RJSC)
2	Trade License	Gazipur City Corporation
3	TIN Certificate	National Board of Revenue Taxes Circle-161, Taxes Zone- 8, Dhaka
4	VAT Certificate	Custom, Excise and VAT Commissionarate, National Board of Revenue, Dhaka (North) Tangi Division
5	Import Registration Certificate (IRC)	Office of the Chief Controller of Imports and Exports
6	Export Registration Certificate (ERC)	Office of the Chief Controller of Imports and Exports
7	Fire Licence	Bangladesh Fire Service and Civil Defence, Dhaka
8	Environment Certificate- Vatinary Madicine (Formula)	Department of Environment, Gazipur
9	Certificate for Licence Manufacture Drugs	Directorate General of Drug Administration & Licencing Authorities (Drugs)
10	ISO Certification	QFS Management System LLP, India
11	Certificate of Good Manufacturing Practice (GMP) for Pharmaceutical Product(s)	Ministry of Health and Family Welfare
12	Export and Import Permit for Fisheries and Food Product	Department of Fisheries, Gazipur
13	Livestock Food Product Export, Import and Marketing (Category 2) License	Department of Livestock Services, Dhaka

Business Strategies:

- Utilizing the government support: The government usually tends to favor this industry. As a result, the government provides them with all of the assistance and support they require.
- Local market share: Competitors always try to increase their percentage of market share. So, Al-Madina Pharmaceuticals Limited will concentrate more to increase its market share.
- Inventory management system: Al-Madina Pharmaceuticals Limited will improve the existing inventory management system.
- Quality and control: Al-Madina Pharmaceuticals Limited will maintain the quality of its products in accordance with international standards.
- International market: Al-Madina Pharmaceuticals Limited will focus on international market to expand in the future.

SWOT Analysis:

SWOT analysis is the acronym for strength, weakness, opportunities, and threats which are a structured planning method that evaluates those four elements of a project or business venture.

Strength

- We provide high technology, high quality and affordable medicine
- Excellent transport system
- Strong chemistry, qualified employees, and process reengineering capabilities
- High ethical standards and rules in order to contribute meaningfully to people's well-being.
- Capability of inventing medicine benchmark
- Skilled workers
- Large customer Base
- Highly skilled sales forces & very efficient & wide distribution channels.
- Good reputation with a strong brand image.

Weakness

- Low investments in innovative R&D
- Allocation of resources such as human resource, financial resource, technical resource, physical resources and informational resources can be hard sometimes.
- the loss of late introduction of new products
- Rapidly increasing costs of skilled manpower such as scientists, regulatory compliance personnel, pharmaceutical personal, lawyer are pushing up the cost of innovation.

Opportunities

- Bangladesh is currently producing life-saving international-standard drugs, and the country is on the verge of achieving pharmaceutical self-sufficiency.
- Bangladesh presently exports medications to roughly 30 nations, with plans to expand further next year.
- Intensive Government support.
- Invention of new products.
- Gaining market share from the existing rivals by offering new innovative product.
- This industry is often favored by the government. The laws and taxes are often in their favor.

Threats

- The pharmaceutical industry is becoming increasingly competitive. As a result, businesses must compete in the market with the innovative products offered by other companies
- Increasing the cost of labor, particularly basic wages has an impact on the total cost of manufacturing and on the selling prices of medications.

Qualitative Justification:

Some of the qualitative factors that help differentiate the Al-Madina Pharmaceuticals Limited from their competitors and enable them to compete successfully in the industry are as follows:

The Company has

- skilled and experienced management, field force and workers.
- Equipped with modern machineries to manufacture pharmaceuticals products.
- Ensured product quality as International Standard.
- A strong research and development department.
- Proper strategic planning to develop business.
- Sophisticated fundamental marketing techniques.
- Strong distribution channels through which they can smoothly supply their products.
- Good corporate governance which is prevailed in the company.

Management Appreciation:

The Board of Directors appreciate the contribution made and support and cooperation given by the officers, staff, workers, customers, creditors, banks, insurance, utility providers, Bangladesh securities and exchange commission, Dhaka stock exchange and Chittagong stock exchange, central depository Bangladesh ltd and government in particular.

Thanks to all of you

On behalf of the board of directors



Md. Billal Hossain
Chairman.

Independent Auditor's Report to the Shareholders of
Al-Madina Pharmaceuticals Limited
Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Al-Madina Pharmaceuticals Limited (the Company), which comprise the statement of financial position as at 30 June 2025 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 30 June 2025 and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and in forming our opinion thereon and we do not provide a separate opinion on these matters. opinion on these matters.

Key audit matter description	How the scope of our audit responded to the key audit matter
Revenue	
ISAs require that, as part of our overall response to the risk of fraud, when identifying and assessing the risks of material misstatement due to fraud, we evaluate which types of revenue or revenue transactions might give rise to potential fraud risks The Company sells different kinds of pharmaceuticals products across all geographical areas in Bangladesh. We have specifically focused this key audit matter to cut-off and occurrence for revenue recorded within 30 June 2025. Pressures to meet stakeholders' expectations could provide incentives to record revenues where controls of the goods have not passed. The associated disclosure is included within Note 21. For specific detail on the Company's accounting policy, please see Note 3.01.	**Audit procedures performed** We performed walkthroughs of the revenue cycle at significant components to gain an understanding of when the revenue should be recognized, to map out the relevant controls end to end and the processes in place. We assessed the design and implementation of these controls. We tested a sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents. We identified and considered the impact of any credit notes or inventory returns occurring after year-end, including evaluating the impact of any material overdue debts from customers. With regard to the implementation of IFRS 15 "Revenue from Contract with Customers", we verified management's conclusion from assessing different

Key audit matter description	How the scope of our audit responded to the key audit matter
	types of contracts and the accuracy of the revised accounting policies in light of the industry specific circumstances and our understanding of the business. We tested the appropriateness of the accounting treatment on a sample basis. In addition, we verified the accuracy of IFRS 15 related disclosures. **Key observations communicated to the Audit Committee** We were satisfied that the revenue recognition policies have been applied appropriately. Based on the work performed, we concluded that revenue has been recorded appropriately.
Inventory	
At the reporting date, the carrying value of inventory amounted to Taka 24,573,310 which is 4.19% of total assets. Inventories were considered as a key audit matter due to the size of the balance and because inventory valuation involves management judgement. Inventory valuation and existence was an audit focus area because of the number of locations/stores that inventory was held at, and the judgement applied in the valuation of inventory to incorporate inventory shrinkage. According to the Company's accounting policy, inventories are measured at the lower of cost or net realizable value. The Company has specific procedures for identifying risk for obsolete items and measuring inventories at the lower of cost and net realizable value. The associated disclosure is included within Note 6. For specific details on the Company's accounting policy, please see Note 3.04.	**Audit procedures performed** • Assessing the compliance of Company's accounting policies over inventory with applicable accounting standards. • Assessing the inventory valuation process and practices. On major locations, we tested the effectiveness of the key controls. • Assessing the analyses made by management with respect to slow moving and obsolete stock. • Attending inventory count on 30 June 2025 and reconciling the count results to the inventory listings to test the completeness of data. • Comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories. • Reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year. • Evaluating the correctness of the valuation of raw materials and packing material as per FIFO method.
Key audit matter description	**How the scope of our audit responded to the key audit matter**
	• Reviewing the calculation of standard labor hours and their regular comparison with actual labor hours of production; and reviewing the process of valuing work-in-progress.

	Key observations communicated to the Audit Committee We were satisfied that the inventory recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that inventories have been recorded appropriately.
Property, plant and equipment	
At the reporting date, the carrying value of the Company's property, plant and equipment amounted to Taka 295,435,685 The valuation of property, plant, and equipment was identified as a key audit matter due to the significance of this balance to the financial statements, as well as the significance of management's judgements in determining its valuation. In considering the valuation of property, plant, and equipment, we focused on the assessment of the following: • Inherent risks associated with property, plant and equipment. • Potential misstatements in property, plant, and equipment on account of frauds and errors. • Assessment of useful lives of assets. • Assessment of impairment of assets. Inherent risks associated with property, plant and equipment • Property, plant and equipment may include assets that should have been derecognized following sale, other transfer of rights or abandonment. • Expenditure that should have been recognized as property, plant and equipment but has not been so recognized, including capitalized finance costs. • Depreciation may have been incorrectly calculated. • Potential misstatements in property, plant, and equipment on account of frauds and errors • Purchase of an asset at an inflated price especially from a related party. • Wrong write-off of the asset as scrap, obsolescence, missing, donated, or destroyed. • Expenditures for repairs and maintenance recorded as property, plant and equipment or vice versa. • Capitalization of expenditure which are not normally attributable to the cost of the property, plant and equipment.	**Audit procedures performed** • We obtained an understanding of the client and its environment to consider inherent risk related to property, plant, and equipment. Our understanding includes: ➢ Obtaining an understanding of the internal control over property, plant, and equipment. ➢ Assessing the risks of material misstatement and d esigning tests of controls and substantive procedures that cover the following aspects: ✓ Substantiate the existence of property, plant, and equipment. ✓ Establish the completeness of recorded property, plant, and equipment. ✓ Verify the cut-off of transactions affecting property, plant, and equipment. ✓ Establish the proper valuation or allocation of property, plant, and equipment and the accuracy of transactions affecting property, plant, and equipment. ✓ Determine the correctness and appropriateness of classification of property, plant and equipment. • We obtained an understanding of the potential misstatements in property, plant, and equipment on account of frauds and errors. • We evaluated the assumptions made by management in the determination of useful lives to ensure that these are consistent with the principles of IAS 16. "Property, Plant and Equipment". • We compared the useful lives of each class of asset in the current year to the prior year to determine whether there were any significant changes in the useful lives of assets, and considered the reasonableness of changes based on our knowledge of the business and the industry. • We verified records e.g. contractor bills, work orders and certification of work performed by the specialized personnel to ensure that the assets under

Property, plant and equipment	
• Recording of an asset purchased, which in effect has not actually been received by the entity at all. **Assessment of useful lives of assets** Management applies estimates and judgements in its determination of useful lives of assets and reviews the useful lives of assets at each financial year end and adjusts for changes, where appropriate **Impairment of assets** At the end of each reporting period, management assesses whether there is any indication that an asset may be impaired. If any such indication exists, management estimates the recoverable amount of the asset. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. The associated disclosure is included within Note 4. For specific details on the Company's accounting policy, please see Note 3.02.	construction or pending installation and not yet ready for intended use are classified as work in progress. • We also verified the date on which the assets are moved from the capital work in progress account to the property, plant and equipment (the date on which the asset is ready for intended use), so that the depreciation on property, plant and equipment may be computed correctly. • We reconciled the movement of capital work in progress from opening to closing, specifically verifying additions during the year, capital assets completed during the year and impairment of any opening capital work in progress items. • We assessed whether there are circumstances that indicate a possible impairment of property, plant and equipment and if such circumstances exist, how the same have been dealt with by the entity¬. **Key observations communicated to the Audit Committee** We were satisfied that the property, plant and equipment recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that property, plant and equipment have been recorded appropriately.

Other Matter
As per Section 11(a) of the Companies Act 1994 (Amended 2020) requires public companies to include "PLC" in their company name which was not complied.

However, our opinion is not modified in respect of these matters.

Reporting on Other Information
Management is responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If we identify such material inconsistencies or apparent material misstatement, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in respect of these matters.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

  •Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report the following:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;

c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts; and

d) the expenditure incurred was for the purposes of the Company's business.

Firm's Name	:	Anil Salam Idris & Co., Chartered Accountants
Firm's Registration Number	:	P-50874/2023
Signature	:	
Engagement Partner Name	:	Md. Anwar Hossain, FCA Managing Partner/ Enrollment No. 1415
DVC Number	:	2510061415AS201981
Date	:	06 October 2025

Al-Madina Pharmaceuticals Ltd
Statement of Financial Position
As at 30 June 2025

Assets	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Non-Current Assets			
Property Plant and Equipment	4.00	295,435,685	296,039,834
Right-of-Use Asset (ROU)	5.00	11,550,405	12,833,784
		306,986,090	**308,873,618**
Current Assets			
Inventories	6.00	24,573,310	24,255,210
Inventories in Transit	7.00	-	6,428,256
Trade Receivables	8.00	211,252,592	201,164,450
Advance Deposit and Pre-payments	9.00	37,245,674	32,434,263
Cash and Cash Equivalents	10.00	5,817,374	50,231,137
		278,888,951	**314,513,316**
Total Assets		**585,875,041**	**623,386,934**
Shareholder's Equity And Liabilities			
Equity			
Share Capital	11.00	204,000,000	204,000,000
Retained Earnings	12.00	77,475,569	72,979,843
Revaluation Reserve	13.00	138,967,050	138,967,050
		420,442,619	**415,946,893**
Non-Current Liabilities			
Deferred Tax Liabilities	14.00	6,122,958	9,721,790
Long Term Loan	15.01	249,680	3,697,968
Lease Obligation	16.03	-	1,548,216
		6,372,638	**14,967,974**
Current Liabilities & Provisions			
Long Term Loan (Current portion)	15.01	3,294,066	2,666,500
Lease Obligation (Current portion)	16.03	-	1,155,369
Short Term Loan	17.00	106,136,678	140,447,626
Accounts Payable	18.00	4,130,200	3,510,400
Liabilities for Expenses	19.00	21,506,219	21,399,718
Provision for Income tax	20.00	23,992,620	23,292,455
		159,059,784	**192,472,068**
Total Liabilities		**165,432,422**	**207,440,042**
Total Shareholders' Equity And Liabilities		**585,875,041**	**623,386,934**
Net Asset Value Per Share (NAVPS) with revaluation	28.00	**20.61**	**20.39**
Net Asset Value Per Share (NAVPS) without revaluation	29.00	**13.80**	**13.58**

The annexed notes are an integral part of these financial statements.

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.

Dated: Dhaka
06 October 2025

Anil Salam Idris & Co.
Chartered Accountants
Firm's FRC Enlistment No.: CAF-001-100

Md. Anwar Hossain, FCA
Managing Partner
ICAB Enrollment No: 1415
FRC Enlistment No.: CA-001-282
DVC No.: 2510061415AS201981

Al-Madina Pharmaceuticals Ltd
Statement of Profit or Loss and other Comprehensive Income
For the year ended 30 June 2025

	Notes	Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
Sales Revenue	21.00	481,684,250	644,127,729
Less: Cost of Goods Sold	22.00	260,170,983	351,993,106
Gross Profit		**221,513,267**	**292,134,623**
Less: Administrative & General Expenses	23.00	25,130,065	32,506,911
Less: Marketing, Selling & Distribution Expenses	24.00	160,548,532	214,887,306
Operating Profit		**35,834,670**	**44,740,406**
Less: Financial Expenses	25.00	19,483,968	18,115,421
Net Profit / (Loss) for the year before WPPF		**16,350,702**	**26,624,985**
Less: Workers' Profits Participation Funds		778,605	1,267,856
Net Profit / (Loss) before Tax		**15,572,097**	**25,357,129**
Income Tax Expenses			
Less: Current tax	26.00	7,295,203	6,595,038
Deferred Tax Expenses/(Income)	26.00	(3,598,832)	934,194
Net profit after tax for the year		**11,875,726**	**17,827,897**
Other Comprehensive Income:		-	-
Total Comprehensive Income during the year		**11,875,726**	**17,827,897**
Earning Per Share (EPS)	27.00	**0.58**	**0.87**

The annexed notes are an integral part of these financial statements.

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.

Dated: Dhaka
06 October 2025

Anil Salam Idris & Co.
Chartered Accountants
Firm's FRC Enlistment No.: CAF-001-100

Md. Anwar Hossain, FCA
Managing Partner
ICAB Enrollment No: 1415
FRC Enlistment No.: CA-001-282
DVC No.: 2510061415AS201981

Al-Madina Pharmaceuticals Ltd
Statement of Changes in Shareholder's Equity
For the year ended 30 June 2025

Amount in BDT

Particulars	Share Capital	Retained Earnings	Revaluation Reserve	Total
Balance as at 1 July 2024	20,40,00,000	72,979,843	138,967,050	415,946,893
Less Cash Dividend		(7,380,000)	-	(7,380,000)
Profit / (Loss) for the Year		11,875,726	-	11,875,726
Balance as at 30 June 2025	**20,40,00,000**	**77,475,569**	**138,967,050**	**420,442,619**

For the year ended 30 June 2024

Amount in BDT

Particulars	Share Capital	Retained Earnings	Revaluation Reserve	Total
Balance as at 1 July 2023	20,40,00,000	61,301,946	138,967,050	404,268,996
Less Cash Dividend		(6,150,000)		(6,150,000)
Profit /Loss for the year		17,827,897	-	17,827,897
Balance as at 30 June 2024	**20,40,00,000**	**72,979,843**	**138,967,050**	**415,946,893**

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dated: Dhaka
06 October 2025

Al-Madina Pharmaceuticals Ltd
Statement of Cash Flows
For the year ended 30 June 2025

	Notes	Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
A. Cash Flows from Operating Activities:			
Cash Received from Customer		471,596,108	657,827,260
Cash Paid to Suppliers, Employees and Other Expenses		(452,391,709)	(606,788,127)
Net Cash Generated from Operating Activities	31.00	**19,204,398**	**51,039,132**
B. Cash Flows from Investing Activities:			
Acquisition of Property, Plant and Equipment		(16,402,908)	(11,062,642)
Payment against Construction Work in Progress		-	-
Net Cash Flows from/(Used In) Investing Activities		**(16,402,908)**	**(11,062,642)**
C. Cash Flows from Financing Activities:			
Proceed/Repayment of Long Term Loan from Bank		(2,820,722)	(1,510,078)
Issuing of Share Capital		-	-
Dividend Paid		(7,380,000)	(6,150,000)
Proceed/Repayment of Lease Rent		(2,703,585)	(1,400,304)
Proceed/Repayment of Short Term Loan		(34,310,948)	(22,900,708)
Net Cash Flows from Financing Activities		**(47,215,253)**	**(31,961,090)**
D. Increase/(Decrease) in Cash And Cash Equivalents (A+B+C)		**(44,413,763)**	**8,015,400**
E. Cash and Cash Equivalents at the Beginning of the Year		**50,231,137**	**42,215,736**
F. Cash and Cash Equivalents at the End of the Year (D+E)	10.00	**5,817,374**	**50,231,137**
Net Operating Cash Flow Per Share (NOCFPS)	30.00	**0.94**	**2.50**

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dated: Dhaka
06 October 2025

Al-Madina Pharmaceuticals Ltd
Notes to the Financial Statements
As at and for the year ended 30 June 2025

1.00 Reporting entity

1.01 About the company

Al-Madina Pharmaceuticals Limited was established as a private limited company in Bangladesh on July 27, 2006, in accordance with the Companies Act of 1994, as evidenced by Certificate of Incorporation No. C-62976(467)/06. Its commercial operations officially began on October 21, 2007. On January 6, 2022, it transitioned into a public limited company. Furthermore, the company was listed on the Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. on May 29, 2023

The address of the company are as follows:
Registered and Factory Office : 1/1, Tilargati, Kakil, Tongi-1711, Gazipur.
Corporate Head Office: 178-179, Farmgate, Tejturi Bazar Road, Road-23, Ward-39, Tejgaon, Dhaka.

1.02 Nature of the business

The Company is engaged in the manufacturing, buying, selling, refinement, import, export or otherwise of pharmaceuticals, medical and medicinal products, and preparations, patent drugs and proprietary articles of all kinds, whether basic or derived and in all forms. Al-Madina Pharmaceuticals Limited started its journey for veterinary drugs in 2007 and human drugs in 2019. At present, it is manufacturing veterinary drugs such as antibacterial drugs, nutritional products, poultry vaccines, aqua products, daily injectable products etc. and human drugs such as anti-bacterial drugs, anti-fungal drugs, gastro-intestinal drugs, analgesic & anti-inflammatory drugs, vitamins-minerals or supplements, drugs acting on urogenital system and drugs acting on respiratory system etc.

2.00 Basis of preparation of Financial Statements

2.01 Basis of measurement

The financial statements have been prepared based on the principle of a going concern, utilizing the historical cost convention as the primary framework. Additionally, certain land properties have been revalued and incorporated into the reporting. The Company has consistently applied these accounting policies, unless explicitly indicated otherwise, maintaining alignment with previous years' practices.

2.02 Statement of compliance

The financial statements have been meticulously prepared to adhere to the stipulations set forth by the Companies Act of 1994, the Securities and Exchange Rules of 2020, The Value Added Tax and Supplementary Duty Act, 2012, the Income Tax Act 2023 and pertinent local regulations. Furthermore, these statements have been crafted in accordance with the guidelines of the International Financial Reporting Standard (IFRS) and the International Accounting Standards (IAS).

2.03 Presentation of Financial Statements:

The financial statements provided adhere to the guidelines outlined in IAS 1: Presentation of Financial Statements.These financial statements consist of the following components:(a) Statement of Financial Position as of June 30, 2024(b) Statement of Profit or Loss and Other Comprehensive Income for the period from July 1, 2023, to June 30, 2024(c) Statement of Changes in Shareholders' Equity for the period from July 1, 2023, to June 30, 2024(d) Statement of Cash Flows for the period from July 1, 2023, to June 30, 2024(e) Statement of Notes, which includes a summary of significant accounting policies and explanatory information.

2.04 Reporting Period

The financial statements cover a year from July 01, 2024 to June 30, 2025

2.05 Authorization for issue

The financial statements were approved by the Board of Directors and authorized for issue on 06 October 2025.

2.06 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/BDT), which is the Company's functional currency.

2.07 Use of Estimates and Judgments

Preparation of financial statements in accordance with IFRSs and IASs necessitates managerial assessments, projections, and assumptions that impact the implementation of accounting policies and the presentation of asset, liability, income, and expense figures, as well as disclosures regarding contingent assets and liabilities, both during the reporting period and at the statement date.

Discrepancies between these projections and actual outcomes are possible. The assessments and underlying presumptions are regularly evaluated. Any modifications to accounting assessments are recognized in the reporting period in which they are altered and in any subsequent periods affected.

Notably, the key areas of estimation, inherent uncertainty, and pivotal judgments in the application of accounting policies that exert the most substantial influence on the figures acknowledged in the financial statements encompass aspects like depreciation, inventory assessment, accrued liabilities, and other payables."

2.08 Business Risk

Adhering to IFRS 7: Financial Instruments, the financial statement has been formulated with consideration of credit risk, liquidity risk, and market risk.

Credit Risk: The Company operates under a credit policy that guides credit issuance. Security measures, such as obtaining blank cheques from customers and counterparties, are implemented during credit sales, minimizing credit risk exposure.

Liquidity Risk: Liquidity risk arises from financial obligations. The Company's sales team is dedicated to adhering to a systematic collection plan for sales proceeds. As a result, the Company's liquidity risk is kept at a minimum.

Market Risk: Market risk hinges on factors like raw material supply, political stability, and environmental conditions. The Company has a well-defined strategy in place to mitigate potential market risks.

2.09 Going Concern

The presented financial statements have been formulated with consideration of the company's ability to operate as a going concern. The company possesses ample resources to sustain its operations in the foreseeable future. In light of this, the board of directors persists in utilizing the going concern premise for the preparation of the financial statements. At present, the company's existing resources and credit arrangements are deemed satisfactory to fulfill the immediate needs of its ongoing business activities.

2.10 Statement of cash flows

The statement of cash flows has been crafted in adherence to the guidelines outlined in IAS 7, "Statement of Cash Flows," employing the direct method. Additionally, a reconciliation of Net Operating Cash Flow stemming from operating activities has been generated, encompassing the indirect method.

3.00 Significant Accounting Policies

The accounting principles and policies pertaining to significant components of the financial statements, as detailed below, have been consistently employed across all periods presented within these financial statements.

3.01 Revenue Recognition

In alignment with the stipulations outlined in IFRS 15, "Revenue," revenue receipts stemming from customer transactions related to sales are acknowledged at the point when products are dispatched to customers. This is contingent upon the pivotal moment when the substantial risks and rewards associated with ownership have been transferred to the purchaser. Moreover, recognition takes place when the recovery of consideration is deemed likely, the related costs and potential product returns can be reasonably estimated, and there exists no ongoing managerial involvement with the merchandise.

3.02 Property, Plant and Equipment

(a) Recognition and Measurement

In conformity with the stipulations outlined in IAS 16, "Property, Plant and Equipment," the presentation of these items has been carried out either at their historical cost or revalued amount, less the accumulated depreciation. The cost of acquiring an asset encompasses its initial purchase price and any costs directly linked to rendering the asset operational for its intended purpose. This incorporates expenses such as inbound freight, duties, and non-refundable taxes.

(b) Maintenance Activities

The company bears maintenance expenses for its significant property, plant, and equipment assets. Costs associated with repairs and maintenance are expensed as they are accrued.

(c)Depreciation

Depreciation is allocated to systematically distribute the cost of assets post-commissioning over the duration of their anticipated useful lives, following the guidelines set forth in IAS 16, "Property, Plant and Equipment." The method employed for this purpose is the reducing balance basis.

Category of Fixed Assets for Depreciation	Depreciation Rate
Land and land development	-
Factory building and Construction	5.00%
Plant and Machinery	15.00%
Generator	15.00%
Air conditioner	15.00%
Water pump	15.00%
Gas line cost	15.00%
Furniture & Fixture	20.00%
Office decoration/ Equipment	15.00%
Television	15.00%
Fridge	15.00%
Electric fittings	15.00%
Motor cycle	15.00%
Computer	20.00%
Computer Printer	15.00%
Photocopy Machine	10.00%
Right-of-use - Covered Van	10.00%
Right-of-use - Motor Bike	10.00%

3.03 Right of Use Assets

The company identifying a contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is conveyed where the customer has both the right to direct the identified asset's use and to obtain substantially all the economic benefits from that use.

3.04 Inventories

In accordance with IAS 2, "Inventories," inventory items are recognized at the lower of their cost or net realizable value. The determination of cost follows the weighted average cost methodology. The cost of inventories encompasses expenditures incurred during routine business operations to bring the inventories to their existing state and location. Net realizable value is calculated based on the projected selling price, minus any additional expenses anticipated for the completion of the sale.

3.05 Trade Receivable

Trade receivables are initially recorded at their invoice value, with an adjustment for estimated Expected Credit Losses (ECL). The determination to label a debt as uncollectible occurs when there is credible evidence of potential non-payment. This evaluation takes into account factors such as the aging of the debt, historical payment patterns, and the prevailing economic conditions. When a trade receivable is deemed irrecoverable, it is promptly written off and recognized as an expense in the profit and loss account. Any subsequent recoveries of previously written-off amounts are recorded as income in the profit and loss account.It's important to note that management views bills receivable for the current year as both financially sound and likely to be collected.

The company computes the Expected Credit Loss (ECL) for each stage using the relevant inputs and subsequently acknowledges an allowance in its financial statements. This allowance lowers the recorded value of the receivables, and any subsequent modifications to this allowance are recorded as either expenses or income in the income statement.

3.06 Cash and Cash Equivalents

The category of cash and cash equivalents encompasses both physical cash on hand and funds held in bank accounts, spanning both current and deposit accounts. These funds are readily accessible to the company for utilization without any constraints. The likelihood of a substantial alteration in their value is minimal.

3.07 Income Taxes:

Current Tax

A provision for income tax has been established in adherence to the stipulations outlined in the Income Tax Act and associated regulations.

Deferred Tax

Deferred income tax is recognized for all transient timing disparities that emerge between the tax base of assets and liabilities and their recorded values within the financial statements, conforming to the guidelines set forth in IAS 12, "Income Taxes." The tax rate prevailing as of the balance sheet date is employed to ascertain deferred income tax.

3.08 Status of Income Tax Assessment

The status of income tax assessment shown in details as under:

Income year	Assessment Year	Assessment completed under ITO 1984
2019-2020	2020-2021	Submitted under Section 82BB
2020-2021	2021-2022	Submitted
2021-2022	2022-2023	Submitted
2022-2023	2023-2024	Submitted
2023-2024	2024-2025	Submitted

3.09 VAT (Value Added Tax):

The Company submitted the required return as per Value Added Tax and Supplementary Duty Act 2012.

3.10 Employees Benefit Plans

Workers Profit Participation Fund and Welfare Fund

The company routinely designates 5% of the net profit before tax to this fund, as dictated by the stipulations outlined in the Bangladesh Labor Law 2006, amended up to 2013. Under this act, the fund is distributed into three categories: the Employee Welfare Fund, the Bangladesh Workers Welfare Foundation, and the Workers Profit Participation Fund, in the proportions of 10%, 10%, and 80%, respectively.

3.11 Provisions

A provision is documented within the statement of financial position when the company possesses a legal or implicit obligation stemming from a prior event. This obligation is anticipated to necessitate an outflow of economic resources, and a dependable estimate can be established for the obligation's value. Provisions are generally assessed at the most accurate projection of the outlay necessary to settle the current obligation at the date of the statement of financial position. In cases where the influence of the time value of money holds significance, the provision amount is computed at the present value of the anticipated expenses essential to satisfy the obligation.

3.12 Interest Income and Borrowing Cost

Interest income is acknowledged based on the accrual principle. On the other hand, borrowing costs are documented as expenses within the time frame in which they are accrued, unless the possibility of capitalization is authorized in accordance with IAS 23, "Borrowing Costs.

3.13 Operating segments

Since the company operates within a single business and geographic segment, there is no need for segment reporting as there are no distinct operating segments to report on.

3.14 Events after the reporting period

Events occurring after the reporting period encompass both positive and negative developments that take place between the end of the reporting period and the date when the financial statements are approved for issuance. These events can be categorized into two distinct types: adjusting events, which offer evidence of conditions that were in existence at the conclusion of the reporting period, and non-adjusting events, which signal conditions that emerged after the reporting period concluded. Please refer to Note 33 in the financial statements for further details regarding these events.

3.15 Earnings Per Share (EPS)

This computation adheres to the specifications set forth in IAS 33, "Earnings Per Share," achieved by dividing basic earnings by the weighted average count of ordinary shares outstanding throughout the year.

3.16 Capital commitment

There is no capital commitment at statement of financial position date.

3.17

The following IAS/IFRS are applicable for the preparation of financial statements for the period under review:

Name of the IAS	IAS No	Status
Presentation of Financial Statements	1	Applied
Inventories	2	Applied
Statement of Cash Flows	7	Applied
Accounting Policies, Changes in Accounting Estimates and Errors	8	Applied
Events after the Reporting Period	10	Applied
Income Taxes	12	Applied
Property, Plant and Equipment	16	Applied

Name of the IAS	IAS No	Status
Employee Benefits	19	Applied
Accounting for Government Grants and Disclosure of Government	20	N/A
The Effects of Changes in Foreign Exchange Rates	21	Applied
Borrowing Costs	23	Applied
Related Party Disclosures	24	Applied
Accounting and Reporting by Retirement Benefit Plans	26	N/A
Consolidated and Separate Financial Statements	27	N/A
Investment in Associates and Joint Ventures	28	Applied
Interest in Joint Ventures	31	N/A
Financial Instruments: Presentation	32	Applied
Earnings Per Share	33	Applied
Interim Financial Reporting	34	N/A
Impairment of Assets	36	Applied
Name of the IFRS	IFRS No	Status
Provision, Contingent Liabilities and Contingent Assets	37	Applied
Intangible Assets	38	N/A
Financial Instruments: Recognition and Measurement	39	N/A
Investment Property	40	N/A
Agriculture	41	N/A
First Time Adaption of IFRS	1	N/A
Share Based Payment	2	N/A
Business Combinations	3	N/A
Insurance Contracts	4	N/A
Non-current Assets Head for Sale and Discontinued Operations	5	N/A
Exploration for and Evaluation of Mineral Resources	6	N/A
Financial Instruments: Disclosure	7	N/A
Operating Segments	8	Applied
Financial Instruments	9	N/A
Consolidated Financial Statements	10	N/A
Joint Arrangements	11	N/A
Disclosure of Interest in other Entities	12	N/A
Fair Value Measurement	13	Applied
Regulatory Deferral Accounts	14	N/A
Revenue from Contracts with Customers	15	Applied
Leases	16	Applied
Insurance Contracts	17	N/A

3.18 Rearrangement and Reclassification for Comparative Analysis

For the sake of comparison, the financial statements of the previous year have been adjusted by rearranging and reclassifying the figures and account titles as required. This modification has been carried out without introducing any alteration to the reported profit, assets, and liabilities values in the financial statements of both the current and preceding years.

		Amount in BDT	
		30 June 2025	30 June 2024
4.00	**Property, Plant And Equipment**		
	At Cost:		
	Opening Balance	412,163,099	398,079,557
	Add: Addition during the year	16,402,908	14,083,542
	Less: Revaluation of Land	(143,265,000)	-
	Closing Balance	**285,301,007**	**412,163,099**
	Accumulated Deprecation		
	Opening Balance	116,123,265	98,183,885
	Add: Depreciation charged during the year	17,007,057	17,939,380
	Closing Balance	**133,130,322**	**116,123,265**
A	**Written Down Value**	**152,170,685**	**296,039,834**
B	**At Revaluation:-**		
	Opening Balance	143,265,000	-
	Add: Addition during the year	-	-
	Add: Revaluation of Land	-	-
	Closing Balance	**143,265,000**	**296,039,834**
	Total Assets (A+B)	**295,435,685**	**296,039,834**
	Property, Plant And Equipment is given in details in Schedule -I		
5.00	**Right-of-Use Asset (ROU)**		
A	**Cost**		
	Opening Balance	20,750,242	20,750,242
	Add: Additions made during the year	-	-
	Closing Balance	**20,750,242**	**20,750,242**
B	**Accumulated Deprecation**		
	Opening Balance	7,916,459	6,490,482
	Add: Deprecation Charged during the year	1,283,378	1,425,976
	Closing Balance	**9,199,837**	**7,916,458**
C	**Written Down Value (A-B)**	**11,550,405**	**12,833,784**
	Right-of-Use Asset is given in details in Schedule -I		
6.00	**Inventories**		
	Raw Material	7,784,100	7,512,560
	Packing Materials	2,733,610	2,631,450
	Finished Goods	14,055,600	14,111,200
		24,573,310	**24,255,210**
7.00	**Inventories In Transit**		
	Raw Material (Import)	-	6,428,256
		-	**6,428,256**
8.00	**Trade Receivable**		
	Trade receivables	212,819,208	202,480,593
	Less: Allowance for Expected Credit Loss 8.01	1,566,616	1,316,143
		211,252,592	**201,164,450**

			Amount in BDT	
			30 June 2025	30 June 2024
8.01	**Allowance for Expected Credit Loss**			
	Opening Balance		1,316,143	1,079,718
	Addition during the year		382,087	363,525
	Less: Written off during the year		(131,614)	(127,100)
	Closing Balance		**1,566,616**	**1,316,143**
9.00	**Advance Deposits and Prepayments**			
	Security Deposit (DESCO)		42,000	42,000
	Security Deposit (Gas Line)		237,300	237,300
	Security Deposit (Brac Poultry)		105,700	105,700
	Security Deposit CDBL		300,000	300,000
	Security Deposit -Electricity,Gazipur City Corporation		112,691	-
	Advance income tax	9.01	31,390,838	30,690,673
	Advance Insurance Bill		125,042	
	Salary and others		-	1,015,490
	Advance for Building Construction	9.02	-	43,100
	Advance for LC Margin		4,932,103	-
			37,245,674	32,434,263
9.01	**Advance Income Tax**			
	Opening Balance		30,690,673	33,038,222
	Advance Tax Paid against Import During the Year		6,964,449	6,595,038
	Advance Tax Deducted (Sale) During the Year		177,675	102,039
	AIT on Sales Tax U/S 53BBBB		153,079	-
	Less:-Adjustment During the year		(6,595,038)	(9,044,626)
			31,390,838	**30,690,673**
9.02	**Advance for Building Construction**			
	Opening Balance		43,100	1,979,100
	Addition during the year		-	
	Less: Adjustment during the year		43,100	1,936,000
			-	**43,100**
10.00	**Cash and Cash Equivalents**			
	Cash at Bank	10.01	1,305,968	27,526,837
	Cash in Hand	10.02	4,511,406	22,704,299
			5,817,374	**50,231,137**
10.01	**Cash in Hand**			
	Cash in Head Office		654,323	26,249,195
	Cash in Factory		651,645	1,277,643
			1,305,968	**27,526,837**
10.02	**Cash at Bank**			
	Islami Bank Ltd., CA No.-280815		829,713	629,868
	Shahjalal Islami Bank Ltd. CA No. 00751		66,978	109,856
	Pubali Bank Ltd. A/C No-28873		445,036	215,937
	Pubali Bank Ltd. A/C No-8118		66,467	60,827
	IFIC Bank Ltd. A/C No-8041		267,374	1,429,391
	Al-Arafah Islami Bank Ltd. A/C-8113		801,494	238,109
	Dutch Bangla Bank Ltd A/C No-124169		384,783	221,734
	Dutch Bangla Bank Ltd A/C No-1027		-	19,533
	Shahjalal Islami Bank Ltd. CA No. 113		599,292	19,678,498
	Shahjalal Islami Bank A/C No. 00139		93,208	100,546
	Dutch Bangla Bank Ltd A/C No-4392		577,265	-
	Dutch Bangla Bank Ltd A/C No-45863		3,735	-
	Islami Bank Ltd., CA No.-3302		252,906	-
	Shahjalal Islami Bank A/C No. 00158		123,157	-
			4,511,406	**22,704,299**

	Amount in BDT	
	30 June 2025	30 June 2024

11.00 Share Capital

(i) Authorized:

30,000,000 Ordinary Shares of Taka 10/- each	**300,000,000**	**300,000,000**

(ii) Issued, Subscribed & Paid up Capital:

a) By Cash:		
11,900,000 Ordinary Shares of Taka 10/- each fully paid-up in cash	119,000,000	119,000,000
(b) Other than Cash:		
8,500,000 Ordinary Shares of Taka 10/- each fully paid-up for consideration other than cash	85,000,000	85,000,000
	204,000,000	**204,000,000**

The above balance has been received from the following :

Name	Designation	% of Shares		No. of Share	No. of Share
		30-06-2025	30-06-2024	30-06-2025	30-06-2024
Directors					
MD. Billal Hossain	Chairman	20.96%	20.96%	4,275,000	4,275,000
MD. Zakir Hossain Patwary	Managing Director	31.43%	31.43%	6,412,500	6,412,500
MD. Kamrul Alam	Director	17.46%	17.46%	3,562,500	3,562,500
		69.85%	69.85%	14,250,000	14,250,000
Others					
Foreign investors		-	-		
Institutions		5.49%	3.72%	1,119,900	758,880
General shareholders		24.66%	26.43%	5,030,100	5,391,120
		30.15%	30.15%	6,150,000	6,150,000
		100.0%	**100.0%**	**20,400,000**	**20,400,000**

12.00 Retained Earnings

Opening Balance	72,979,843	61,301,946
Net Profit/(Loss) for the year	11,875,726	17,827,897
Less: Paid Cash Dividend	7,380,000	6,150,000
Closing Balance	**77,475,569**	**72,979,843**

The rationale behind the adjustment for the prior year is elaborated upon in Note 14.

13.00 Revaluation Reserve

On June 30, 2021, Masih Muhith Haque & Co., Chartered Accountants, undertook the revaluation process. Initially, the Land and Land Development were valued at Tk 4,185,000. Following the revaluation, these assets were assessed at Tk 147,450,000, indicating a significant surge of Tk 143,265,000 in their worth. Additionally, a revaluation reserve was recognized, net of taxation adjustments.

Revaluation Reserve of Land and Land Development	138,967,050	138,967,050
	138,967,050	**138,967,050**

14.00 Deferred Tax Liabilities

Deferred Tax Operational liabilities	14.01	1,825,008	5,423,840
Deferred Tax on Revaluation Reserve	14.02	4,297,950	4,297,950
		6,122,958	**9,721,790**

		Amount in BDT	
		30 June 2025	30 June 2024
14.01 Deferred Tax Operational liabilities			
Opening Balance		5,423,840	(27,744,979)
Add: Deferred tax expense/(Income) during the year	26.02	(3,598,832)	33,168,819
		1,825,008	**5,423,840**
14.02 Deferred Tax on Revaluation Reserve		**4,297,950**	**4,297,950**
15.00 Long Term Loan			
Shahjalal Islami Bank Ltd		3,543,746	6,364,468
		3,543,746	**6,364,468**
15.01 Long Term Loan			
Non-Current Portion-Shahjalal Islami Bank Ltd		249,680	3,697,968
Current Portion-Shahjalal Islami Bank Ltd		3,294,066	2,666,500
		3,543,746	**6,364,468**
16.00 Lease Obligation			
Covered Van -Ifad Autos Ltd	16.01	-	-
Motor Bike-Shahjalal Islami Bank Ltd	16.02	-	2,703,585
		-	**2,703,585**
16.01 Covered Van -Ifad Autos Ltd			
Opening Balance		-	244,935
Less: Payment during the year		-	244,935
		-	-
16.02 Motor Bike-Shahjalal Islami Bank Ltd			
Opening Balance		2,703,585	3,858,954
Less: Payment during the year		2,703,585	1,155,369
		-	**2,703,585**
16.03 Lease Obligation			
Non-Current Portion		-	1,548,216
Current Portion-Shahjalal Islami Bank Ltd		-	1,155,369
		-	**2,703,585**
17.00 Short Term Loan			
Al-Arafah Islami Bank Ltd (Bai-Muazzal)		11,473,139	11,232,891
Al-Arafah Islami Bank Ltd (MPI-TR)		46,558,997	47,103,735
Shahjalal Islami Bank Ltd.(MPI-TR)		5,196,810	37,506,000
Shahjalal Islami Bank Ltd. (Bai Muazzal)		42,907,732	44,605,000
		106,136,678	**140,447,626**
18.00 Accounts Payable			
Accounts Payable		4,130,200	3,510,400
		4,130,200	**3,510,400**
19.00 Liabilities for Expenses			
Audit Fees		184,000	184,000
Salary & Wages		15,964,500	13,485,006
Utilities Bill		824,836	1,100,726
TDS Payable		236,785	-
VAT Payable		2,037,035	5,040,314
WPPF Payable	19.01	2,032,898	1,492,899
Dividend Payable-2023		94,587	96,773
Dividend Payable-2024		119,079	-
Audit fee on QIO fund		12,500	-
		21,506,219	**21,399,718**

		Amount in BDT	
		30 June 2025	30 June 2024
19.01 WPPF Payable			
Employee welfare fund	19.01.01	196,860	126,786
Bangladesh workers welfare foundation	19.01.02	196,859	287,531
Workers participation fund	19.01.03	1,639,179	1,078,583
		2,032,898	**1,492,899**
19.01.01 Employee welfare fund			
Opening balance		126,786	160,745
Addition during the year		70,074	126,786
Payment during the year		-	160,745
		196,860	**126,786**
19.01.02 Bangladesh workers welfare foundation			
Opening balance		287,531	322,081
Addition during the year		70,074	126,786
Less:-Payment during the year		160,746	161,336
		196,859	**287,531**
19.01.03 Workers participation fund			
Opening balance		1,078,583	1,285,961
Addition during the year		560,596	1,014,285
Less:-Payment during the year		-	1,221,663
		1,639,179	**1,078,583**
20.00 Provision for Income Tax			
Opening Balance		23,292,455	25,742,043
Provision during this year		7,295,203	6,595,038
Less: Adjustment during the year		(6,595,038)	(9,044,626)
		23,992,620	**23,292,455**

		Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
21.00 Sales Revenue			
Export Sales		15,409,921	-
Local Sales	21.01	466,274,329	644,127,729
		481,684,250	**644,127,729**

		Animal Health Products	Pharmaceuticals Products		
21.01	Vatable Sales	173,144,516	228,591,437	401,735,953	593,244,579
	Non Vatable Sales	116,938,709	-	116,938,709	128,262,877
	Less: VAT	22,584,062	29,816,271	52,400,333	77,379,727
		267,499,163	**198,775,166**	**466,274,329**	**644,127,729**

22.00 Cost of Goods Sold			
Raw material consumed	179,357,047	253,435,277	
Packing materials consumed	5,168,775	6,911,897	
Materials consumed	**184,525,822**	**260,347,174**	
Factory Overhead	76,155,681	91,775,770	
Cost of production	**260,681,503**	**352,122,944**	
Add: Opening stock of finished goods	14,111,200	14,552,000	
Less: Closing stock of finished goods	14,055,600	14,111,200	
Less: Cost of Sample	566,120	570,638	
Cost of Goods Sold	**260,170,983**	**351,993,106**	

		Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
22.01	**Raw Materials**		
	Opening Stock	7,512,560	9,012,450
	Add: Purchase during the year	179,628,587	251,935,387
	Less: Closing Stock	7,784,100	7,512,560
	Raw material consumed	**179,357,047**	**253,435,277**
22.02	**Direct Packing Materials**		
	Opening Stock	2,631,450	2,749,320
	Add: Purchase during the year	5,270,935	6,794,027
	Less: Closing Stock	2,733,610	2,631,450
	Packing materials consumed	**5,168,775**	**6,911,897**
22.03	**Factory Overhead**		
	Direct Wages , Salary and Bonus	38,151,100	51,004,936
	Laboratory Reagent	51,600	92,312
	Fuel & Lubricant	701,577	1,098,219
	Daily Labour Expenses	570,100	1,298,747
	Electricity bill (Factory)	11,402,224	11,889,213
	Mobile Expenses	288,000	517,300
	Spare Parts	101,200	133,150
	Insurance Premium	1,045,221	1,526,600
	Depreciation Expenses	16,421,969	17,305,886
	Stationery Expenses	124,660	212,831
	License renewal and holding tax	590,068	379,621
	Employee conveyance Expenses	401,200	519,576
	Worker Welfare Expenses	345,599	565,349
	Toll Expenses	5,479,742	4,781,374
	Repair and Maintenance	140,420	248,656
	Medical Expenses	101,000	202,000
	Factory Rent Expenses	240,000	240,000
		76,155,681	**91,775,770**
23.00	**Administrative & General Expenses**		
	Salary,Bonus & Allowance	16,093,800	22,858,539
	Office Rent	600,000	600,000
	Stationary	111,458	214,571
	Entertainment	90,100	228,100
	Audit Fees	184,000	184,000
	Electricity bill	708,860	612,742
	Social Welfare Expenses	110,100	345,953
	Employee Conveyance Expenses	560,112	672,123
	Bank charge	78,250	115
	GAS LPG Expenses	21,855	22,954
	Fuel	111,300	220,010
	Water bill	116,521	106,819
	Postage (Local)	15,100	26,680
	Internet Bill	51,500	92,124
	Newspaper Expenses	2,808	320
	Uniform		5,300
	Medical Expenses	111,600	185,991
	Misc. Expense	5,300	9,600
	Maintenance	101,600	158,003
	Depreciation Expenses	491,733	531,500
	Telephone	4,969	3,059
	Mobile bill	330,000	504,700
	Daily Labour Expenses	44,500	59,900
	Employee Welfare Expenses	191,400	372,268
	Product Registration and renewal Govt. Fee	652,550	448,140
	Attendance Fee of Board meeting	24,000	24,000
	Director Salary	3,900,000	3,900,000
	Credit Rating Expenses	23,400	23,400
	Consultancy Fees	50,000	-
	Listing Fee and Expenses (DSE ,CSE and CDBL)	96,000	96,000
	Audit fee on QIO Fund	50,000	-
	Export expenses	110,000	-
		87,250	-
		25,130,065	**32,506,911**

		Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
24.00	**Marketing, Selling and Distribution Expenses**		
	Salary ,Bonus & Allowance	143,855,600	192,369,604
	Depot Rent	2,256,600	158,500
	Stationery	190,300	300,124
	Entertainment	81,600	118,828
	Electricity bill	67,837	96,934
	Social Welfare Expenses	210,242	545,764
	Employee Conveyance Expenses	6,402,250	9,811,300
	Bank charges	151,974	-
	GAS LPG Expenses	40,420	53,765
	Fuel	3,040,506	5,396,120
	Water bill	20,950	49,993
	Postage (Local)	11,490	245,915
	Internet Bill	54,619	70,200
	Newspaper Expenses	3,290	3,280
	Sample Expenses	566,120	570,638
	Uniform		7,042
	Medical Expenses	90,600	286,254
	Miscellaneous Expenses	15,928	21,300
	Maintenance	98,427	132,546
	Business Promotional Expenses	281,560	520,518
	Depreciation Expenses	1,376,733	1,527,970
	Mobile Expenses	527,600	702,700
	Daily Labour Expenses	187,900	522,386
	Expected Credit Loss Expense	382,087	363,525
	License renewal expenses	25,100	12,100
	Doctor visit expenses	477,300	800,000
	Customer visit expenses	131,500	200,000
		160,548,532	**214,887,306**
25.00	**Financial Expenses**		
	Interest Expenses	19,381,947	18,115,421
	Foreign Exchange Loss 25.01	102,021	-
		19,483,968	**18,115,421**

25.01 Foreign Exchange (Gain)/Loss

Particulars	Rate USD to BDT	Invoiced Value in BDT	Total Amount
Export Sales	120	64,850.63	7,782,076
Export Sales	122	62,523.32	7,627,845
	Sub-Total	**127,373.95**	**15,409,921**
(Recognised Amount) Ref:AIBLPLC/GUL/FEX/2025/1716	120.27	127,274.95	(15,307,900)
		Difference (Gain)/ Loss	**102,021**

The Company has foreign exchange loss of Tk 102,021 during the year ended 30th June 2025

26.00	**Income Tax Expenses**		
	Current Tax	7,295,203	6,595,038
	Deferred Tax expenses/(Income)	(3,598,832)	33,168,819
		3,696,371	**39,763,857**

		Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
26.01	**Current Tax Calculation**		
	Profit from operation before tax	15,572,097	25,357,129
	Sub total	**15,572,097**	**25,357,129**
	Add: Inadmissible Expenses		
	Accounting Depreciation for separate consideration	17,007,057	17,939,380
	Lease - Depreciation	1,283,378	1,425,976
	Lease - Interest expenses	191,985	385,000
	Expected Credit Loss Expense	382,087	363,525
	Total	**34,436,604**	**45,471,010**
	Less: Admissible Expenses		
	Lease Payment	2,703,585	1,400,304
	Depreciation as per 3rd Schedule of ITA -2023	23,590,498	22,327,778
	Total Taxable Income from Business	**8,142,521**	**21,742,928**
	Tax Rate (In Percentage)	22.50	22.50
	A) Income Tax	**1,832,067**	**4,892,159**
	B) Minimum Tax:		

From Turnover:		Turnover (Taka)		
Turnover	@ 1%	481,684,250	4,816,843	3,864,766
			4,816,843	**3,864,766**
	C. Tax Deduct at source (AIT)		7,295,203	6,595,038
	Current Tax (whichever is higher between (A ,B and C)		**7,295,203**	**6,595,038**
26.02	**Deferred Tax Calculation**			
	Accounting Base Carrying Amount of Property, Plant and Equipment (Excluding Land)		138,353,582	138,957,731
	Less: Tax Base carrying Amount of Property, Plant and Equipment (Excluding Land)		128,675,824	113,535,636
	Accounting Base Carrying Amount of Allowance for Expected Credit Loss		(1,566,616)	(1,316,143)
	Net Temporary Difference of taxable/(Deductible) during the year		8,111,143	24,105,952
	Closing Deferred Tax Liabilities/(Assets)		**1,825,007**	**5,423,839**
	Opening Deferred Tax Liabilities		5,423,839	(27,744,980)
	Deferred tax Expenses/(Income) During the year		(3,598,832)	33,168,819
	Closing Deferred Tax Liabilities		**1,825,007**	**5,423,839**
27.00	**Earning Per Share (EPS)**			
	Net profit after tax for the year		11,875,726	17,827,897
	Weighted Average Number of Shares used to compute EPS		20,400,000	20,400,000
	Earning Per Share (EPS) without other comprehensive income		**0.58**	**0.87**
28.00	**Net Asset Value per share (NAVPS) with revaluation**			
	Total Assets		585,875,041	623,386,934
	Total Liabilities		165,432,422	207,440,042
	Net Asset		**420,442,619**	**415,946,892**
	Number of Ordinary Shares		20,400,000	20,400,000
	Net Asset Value per share (NAVPS) with revaluation		**20.61**	**20.39**

		Amount in BDT	
		01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
29.00	**Net Asset Value Per Share (NAVPS) without revaluation**		
	Total Assets	585,875,041	623,386,934
	Total Liabilities	165,432,422	207,440,042
	Less: Revaluation Reserve	138,967,050	138,967,050
	Net Asset	**281,475,569**	**276,979,842**
	Number of Ordinary Shares	20,400,000	20,400,000
	Net Asset Value Per Share (NAVPS) without revaluation	**13.80**	**13.58**
30.00	**Net Operating Cash Flow Per Share (NOCFPS)**		
	Net Cash Generated from Operating Activities	19,204,398	51,039,132
	Weighted Average Number of Ordinary Shares	20,400,000	20,400,000
	Net Operating Cash Flow Per Share (NOCFPS)	**0.94**	**2.50**
31.00	**Reconciliation of net profit with cash flows from operating activities**		
	Net profit after tax	11,875,726	17,827,897
	Depreciation	18,290,435	19,365,356
	(Increase)/Decrease in Inventories	(318,100)	2,058,560
	(Increase)/Decrease in Transit	6,428,256	(3,151,171)
	(Increase)/Decrease in Trade Receivable	(10,088,142)	13,699,531
	(Increase)/Decrease in Advance Deposit & Pre-Payments	(4,811,411)	3,596,059
	Increase/(Decrease) in Accounts Payable	619,800	(330,045)
	Increase/(Decrease) in Liabilities for Expenses	106,501	(511,660)
	Increase/(Decrease) in Provision for income tax	700,165	(2,449,588)
	Increase/(Decrease) in Deferred Tax Liabilities	(3,598,832)	33,168,819
		19,204,398	**83,273,756**

Amount in BDT	
01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024

32.00 Information as per Companies Act, 1994

32.01 Attendance Status of Board Meeting of Directors

During the year, 4 Board Meetings were held. The attendance status of the meetings are as follows:

Name of Directors	Position	Meeting Held	Total Fee
Billal Hossain	Chairman	4	8,000
Mohammad Zakir Hossain Patowary	Managing Director	4	8,000
Md. Kamrul Alam	Director	4	8,000

32.02 Related Party Transaction

During the year under audit, the company carried out no transactions with related parties in the normal course of business and on arms, length basis in accordance with the provisions of Para 17 of IAS 24 "Related Party Disclosure":

(a) Short-term employee benefits:

Name	Designation	Monthly Salary	Total Salary	Board Meeting Fee
Billal Hossain	Chairman	100,000	1,200,000	8,000
Mohammad Zakir Hossain Patowary	Managing Director	150,000	1,800,000	8,000
Kamrul Alam	Director	75,000	900,000	8,000
Total			**3,900,000**	**24,000**

(b) post-employment benefits Nil

(c) other long-term benefits Nil

(d) termination benefits Nil

(e) share-based payment benefits Nil

32.03 Payments to Director by the company during the year:

Particulars	30 June 2025
A. Managerial remuneration paid or payable during the year to the directors, a managing agent or manager.	3,900,000
B. Expenses reimbursed to the managing agent.	
C. Commission or other remuneration payable separately to managing agent or his associate.	
D. Commission or other remuneration payable separately to managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.	
E. The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the managing agent or his associate during the financial year.	
F. Any other perquisites or benefits in cash or in kind.	
G. Other allowances and commission including guarantee commission.	
H. Pensions etc.	

32.04 Employee position of Al Madina Pharmaceutical Limited as per requirement of schedule XI, part II, Para-3

As of June 30, 2025, the company had a staff of 545 members, in contrast to 683 individuals on June 30, 2023. It's worth mentioning that every employee received an annual total salary surpassing Tk. 36,000.

33.00 Event after Reporting Period

Proposed Dividend Allocation: Board Recommendation and Upcoming Shareholders' Approval

During their meeting on October 6, 2025, the Board of Directors has put forth a recommendation for the allocation of dividends based on retained earning excluding revaluation reserves. The proposal consists of a cash dividend (Excluding directors or sponsors) was 12% per share and 1% Cash Dividend for Sponsors and or Directors. The total proposed cash dividend was BDT 7,380,000 for general Shareholders and 1,425,000 for Sponsors and or Directors. These recommendations pertain to the fiscal year that concluded on June 30, 2025.

It's important to note that the financial statements for the year ended June 30, 2025, have not yet incorporated the effects of the aforementioned cash and stock dividends. These effects will be recognized in the accounting period when the shareholders' right to receive the dividend payment is officially established.

Other Events

As of the statement of financial position date, no significant events have been identified that necessitate adjustment or disclosure in these financial statements.

Al-Madina Pharmaceuticals Ltd.
Property, Plant and Equipment's Schedule
As at 30 June 2025

a) At Cost

SL No	Particulars	Cost				Disposal/Depreciation					Written Down Value
		As at 01 July 2024	Addition	Disposal	As at 30 June 2025	Rate	As at 01 July 2024	During the Year	Disposal	As at 30 June 2025	As at 30 June 2025
1	Land and land development	13,817,103	-	-	13,817,103		-		-		13,817,103
2	Factory building and Construction	66,337,493	7,551,400	-	73,888,893	5%	18,551,577	2,595,515	-	21,147,092	52,741,801
3	Plant and Machinery	174,856,763	8,552,973	-	183,409,736	15%	88,759,372	13,547,982	-	102,307,354	81,102,382
4	Generator	662,548		-	662,548	15%	618,106	6,666	-	624,772	37,776
5	Air conditioner	1,391,713		-	1,391,713	15%	1,298,359	14,003	-	1,312,362	79,351
6	Water pump	46,459		-	46,459	15%	43,118	501	-	43,619	2,840
7	Gas line cost	1,136,507		-	1,136,507	15%	1,060,271	11,435	-	1,071,706	64,801
8	Furniture & Fixture	2,612,581		-	2,612,581	20%	1,587,876	204,941	-	1,792,817	819,764
9	Office decoration / Equipment	1,381,561		-	1,381,561	15%	780,824	90,111	-	870,935	510,626
10	Television	9,835		-	9,835	15%	9,175	99	-	9,274	561
11	Fridge	22,257		-	22,257	15%	20,764	224	-	20,988	1,269
12	Electric fittings	4,246,319	298,535	-	4,544,854	15%	1,642,549	415,434	-	2,057,983	2,486,871
13	Motor cycle	1,023,500		-	1,023,500	15%	947,505	11,399	-	958,904	64,596
14	Computer	1,278,710		-	1,278,710	20%	741,425	107,457	-	848,882	429,828
15	Computer Printer	13,000		-	13,000	15%	12,034	145	-	12,179	821
16	Photocopy Machine	61,750	-	-	61,750	10%	50,308	1,144	-	51,452	10,298
Sub Total -2025		**268,898,099**	**16,402,908**	**-**	**285,301,007**		**116,123,265**	**17,007,057**	**-**	**133,130,322**	**152,170,685**
17	Right-of-use - Covered Van	13,328,000		-	13,328,000	10%	5,146,871	818,113	-	5,964,984	7,363,016
18	Right-of-use - Motor Bike	7,422,242		-	7,422,242	10%	2,769,588	465,265	-	3,234,853	4,187,389
Sub Total -2025		**20,750,242**	**-**		**20,750,242**		**7,916,459**	**1,283,378**		**9,199,837**	**11,550,405**
	Total at Cost	**289,648,341**	**16,402,908**		**306,051,249**		**124,039,724**	**18,290,435**		**142,330,159**	**163,721,090**

b) At revaluation

19	Land and land development	143,265,000			143,265,000		-			-	143,265,000
Sub total -2025		**143,265,000**			**143,265,000**					**-**	**143,265,000**
As on 30 June 2025 (a+b)		**432,913,341**	**16,402,908**	**-**	**449,316,249**		**124,039,724**	**18,290,435**	**-**	**142,330,159**	**306,986,090**
As on 30 June 2024		**418,829,799**	**14,083,542**	**-**	**432,913,341**		**104,674,368**	**19,365,356**	**-**	**124,039,724**	**308,873,617**

Depreciation Charged to :	**30 June 2025**	
Factory Overhead	16,421,969	30%
Administrative & General Expenses	491,733	60%
Marketing, Selling & Distribution Expenses	1,376,733	10%
Total Taka:	**18,290,435**	

Al-Madina Pharmaceuticals Limited

178-179, Two Star Tower (5th Floor), East Tejturi Bazar, Farmgate, Dhaka-1215

PROXY FORM

I/We.....

of.....

.....being a shareholder of Al-Madina Pharmaceuticals Limited, do hereby appoint Mr./Ms.....of.....

.....

as my/our proxy to attend and vote on my/our behalf at the **19th Annual General Meeting (AGM)** of the Company to be held on on **Thuesday, December 30, 2025 at 11:30** am through digital platform and can be accessible on the following link https://almadinapharma.bdvirtualagm.com

As witness my/our hand this ..... Day of 2025

.....
Signature of Shareholder

No. of Shares held:

Revenue Stamp of Tk. 100/-

.....
Signature of proxy

BO ID No. | | | | | | | | | | | | | | | |

Note:

1. A shareholder entitled to attend and vote in the AGM may appoint a Proxy to attend and vote on his/her behalf.
2. The Proxy Form, duly filed and stamped must be deposited at the Registered Office of the Company or sent through email at anwar.cs.ampl@gmail.com at least 48 hours before the time fixed for the meeting.
3. Signature of the Shareholder(s) must be in accordance with the Specimen Signature recorded with the Company.

.....
(Authorized Signature)

Al-Madina Pharmaceuticals Limited

Al-Madina Pharmaceuticals Ltd.

178-179, Two Star Tower (5th Floor), East Tejturi Bazar, Farmgate, Dhaka-1215

info@almadinapharma.com

+88 02-222245141, +88 02-222245148

www.almadinapharma.com